Stockwinners Market Radar for September 13, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:06 EDT Cathie Wood's ARK Investment bought 15K shares of Nvidia today

20:05 EDT Cathie Wood's ARK Investment bought 250.5K shares of Roku today

19:33 EDT Know Labs announces NYSE listing - Know Labs "announced that, subject to official authorization and meeting all requirements at the time of listing, the Company has been approved to uplist to the NYSE American Exchange in conjunction with an underwritten public offering of the Company's common stock. Upon the start of trading on the NYSE American, the ticker symbol for Know Labs' common stock will change from "KNWN" to "KNW" and the Company's common stock will cease trading on the over-the-counter market. The stock is expected to commence trading on NYSE American at the opening of trading on September 16, 2022."

19:13 EDT Rio Tinto, Baowu form JV to develop Western Range - Rio Tinto and China Baowu Steel Group have agreed to enter into a joint venture with respect to the Western Range iron ore project in the Pilbara, Western Australia, investing $2B combined to develop the mine. Rio Tinto will have a 54% stake in the venture, with Baowu owning 46%. Western Range's annual production capacity of 25M tonnes of iron ore will help sustain production of the Pilbara Blend from Rio Tinto's existing Paraburdoo mining hub. The project includes construction of a primary crusher and an 18 kilometre conveyor system linking it to the existing Paraburdoo processing plant. Construction is expected to begin in early 2023 with first production anticipated in 2025. The construction phase will support approximately 1,600 jobs with the mine requiring about 800 ongoing operational roles which are expected to be filled by existing workers transitioning from other sites in the Paraburdoo mining hub. Rio Tinto's share of the capital costs are already included in the Group's capital expenditure guidance of around $9B-$10B for each of 2023 and 2024. Both parties will pay their portion of capital costs for the development of the mine, and mine operating costs, plus a nominal ongoing resource contribution fee calculated by reference to Western Range production volumes. There is no upfront consideration being paid by either party. Rio Tinto and Baowu have also agreed to enter into an iron ore sales agreement at market prices covering a total of up to 126.5M tonnes of iron ore over approximately 13 years. This volume represents Baowu's 46% interest in the anticipated 275M tonnes of production from Western Range through the Joint Venture.

19:01 EDT MediciNova gets notice of allowance for new patent on MN-001 and MN-002 - MediciNova "announced it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 and MN-002 for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2034. The allowed claims cover the use of MN-001 or MN-002 for reducing a triglyceride blood level, for reducing a total cholesterol blood level, and for reducing a low density lipoprotein blood level. The allowed claims cover oral administration including liquid and solid dosage forms. The allowed claims cover a wide range of doses and a range of different dosing frequencies."

18:39 EDT Microsoft CMO sells $1.33M in common stock - In a regulatory filing, Microsoft disclosed that its CMO Christopher Capossela sold 5K shares of common stock on September 12th in a total transaction size of $1.33M.

18:27 EDT Costco CEO: Expect inflation situation to turn around in 6-12 months - In an interview on CNBC's Mad Money, Craig Jelinek said Costco is very careful on its pricing. "We have a responsibility to be the price police," he added. Costco is not a margin company, it's a volume company, he noted. Jelinek said there is inflation, but it should subside in six months to a year. The company's turnover rate grew during Covid, but it's leveling out now. He's convinced that now is not the time to raise the membership fee.

18:25 EDT Sony's PlayStation showcases 'Tekken 8,' 'God of War Ragnarok' at State of Play - At its State of Play event, Sony's (SONY) PlayStation unit made a number of game announcements for its PlayStation 4, PlayStation 5, and PSVR2 platforms. The company began the show with a trailer for Bandai Namco's (NCBDY) "Tekken 8" for PlayStation 5 and followed with trailers for PlayStation VR titles "Star Wars: Tales from Galaxy's Edge" and interactive card game "Demeo," with no set release dates. Sony then announced that Sega's (SGAMY) "Like A Dragon Ishin" is coming to the West for PS4 and PS5 in February 2023, with other 2023 titles getting trailers including Bandai Namco's "Syn Duality" and Sony-published "Stellar Aside." In addition, Team Ninja premiered a trailer for action game "Rise of the Ronin," which will be PS5 console exclusive coming in 2024. PlayStation closed the showcase with a new trailer for "God of War Ragnarok," coming to PS4 and PS5 November 9, whilst aslo unveiling a new "God of War" themed DualSense controller.

17:55 EDT Stellantis, GM to execute share repurchase transaction - Stellantis (STLA) and General Motors (GM) have executed a share repurchase agreement related to the 69.1M common shares in Stellantis, representing approximately 2.2% of Stellantis' share capital (on a diluted basis), that GM is entitled to receive upon the exercise of equity warrants originally issued by Peugeot S.A. to GM in 2017. The Warrants were issued to GM as part of the purchase by PSA of the Opel Vauxhall automotive business. Upon exercise of the Warrants, Stellantis will also deliver to GM approximately 1.2 million common shares of Faurecia and an aggregate cash amount of approximately EUR130 million for rights to dividends paid by PSA and Stellantis. Pursuant to the SRA, the issue and the repurchase of Stellantis common shares will both occur on September 15. The purchase price paid by Stellantis for the common shares will amount, in total, to EUR 923,247,678 (such amount is based on the volume-weighted average price of one Stellantis common share on the regulated market of Euronext in Milan over the last five trading days). This purchase of Stellantis common shares by Stellantis from GM will be carried out under the authority granted by the general meeting of April 13, 2022.

17:50 EDT Starbucks sees incremental investments in support of reinvention plan - Sees spending slightly more than $1B of incremental investments in FY23.

17:47 EDT Starbucks sees margin expanding in each of next three years - Sees "solid" margin expansion in FY23, with progressively more expansion in FY24 and FY25 as impacts of reinvention plan start to take effect and "amplify."

17:44 EDT Starbucks sees annual global net new store growth about 7% from FY23-FY25 - Sees U.S. annual net new store growth 3%-4% from FY23-FY25. Sees China annual net new store growth roughly 13% from FY23-FY25.

17:41 EDT Starbucks sees global SSS growth reaching 7%-9% from FY23-FY25 - Sees FY23 global SSS growth at high end of range.

17:25 EDT Raytheon, Lockheed Martin JV awarded $311.17M Army contract modification - Raytheon/Lockheed Martin Javelin JV, Tucson, Arizona, was awarded a $311.17M modification to a contract for full-rate production of Javelins. Work will be performed in Tucson, Arizona, with an estimated completion date of November 30, 2026. FY22 Foreign Military Sales funds and Army procurement appropriations funds in the amount of $311.17M were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

17:03 EDT Raytheon expects share repurchase of at least $2.5B in FY22

17:01 EDT Copa Holdings reports August traffic up 2.0% vs. August 2019 levels - Copa Holdings states: "Given the irregular nature of the Company's operations starting in March 2020 due to the Covid-19 pandemic, we are comparing this traffic report to 2019 statistics. Consolidated capacity came in 0.4% higher than August 2019, while passenger traffic increased 2.0%. As a result, system load factor for the month was 86.6%, 1.4 percentage points higher than August 2019."

17:00 EDT Alpha Star Acquisition Corp trading resumes

16:52 EDT Facebook debuts Community Chats to connect your community on Messenger - In an entry on the Messenger blog, the company said it is debuting Community Chats that connects your community in real time on Messenger, and now expanding the experience to more Facebook Groups. The company blogged: "As Mark announced, we'll begin testing the ability to start Community Chats directly in Messenger and expand the chat experience to more Facebook Groups in the coming weeks.With Community Chats, people can connect with their communities in real time around the topics they care about on both Facebook and Messenger via text, audio and video. We've helped more than a billion people connect with loved ones in a trusted space on Messenger, and we know that people want to engage in real time with larger communities over shared interests. Today, Mark Zuckerberg announced we'll begin testing the ability for people to start Community Chats in Messenger in the coming weeks, allowing people to create a Facebook Group, start chats and audio channels, and invite others to join their new group all within the app. We'll also be expanding Community Chats to even more Facebook Groups." Reference Link

16:41 EDT Flowserve sees Q3 EPS impacted by 18c to 22c on period-specific issues - The company states: "Flowserve implemented a new enterprise resource planning system early in the third quarter at certain of its high-volume manufacturing and quick response centers in North America intended to significantly enhance operations and customer experience, and to replace the prior unsupported, legacy system. While most of the company's ERP transitions since 2017 have gone live without operational disruption, the company experienced challenges with this implementation during the first two months of the third quarter that negatively impacted volumes. Flowserve has taken actions to resolve these issues and as a result, the impacted facilities are nearing normal operating levels. Flowserve expects that it will largely recover this quarter's lost volumes in future periods, however it currently anticipates this issue will reduce EPS in the quarter by 10 to 12 cents. Additionally, the company expects to incur certain unanticipated increases in corporate expenses, including Flowserve's annual adjustment for incurred but not reported liability accruals that the company undertakes annually in conjunction with a third-party actuarial consultant. These corporate expenses are expected to impact the company's results by 8 to 10 cents per share in the 2022 third quarter. " CEO Scott Rowe says: "While we are disappointed by these developments, we have confidence that the impact will be largely limited to the third quarter. With respect to the ERP implementation, we have allocated substantial resources to resolve the issues and return the impacted facilities to their traditional production levels. The progress we have made in the past few weeks is significant, which should ensure that the impact to Flowserve and our customers is largely behind us. Despite these challenges, Flowserve has continued to see robust bookings momentum thus far in the quarter, positioning the company to potentially achieve the highest quarterly bookings by value thus far in 2022. The fundamentals of the business are strong, and our traditional end-markets remain supportive, as energy independence and energy security have become national priorities almost globally. In addition, our 3D strategy has proven successful to date and has provided accelerated bookings growth. We expect these trends to continue in future quarters based on the current market environment and that this strength will result in improving financial performance."

16:33 EDT Alpha Star Acquisition, Cyclebit Group enter LOI for business combination - Alpha Star Acquisition announced that it has entered into a non-binding letter of intent, or LOI, for a business combination with Cyclebit Group. Founded in 2012, Cyclebit is a global payments and SaaS provider. Its core products include card acquiring, point-of-sale services and marketplace solutions. Under the terms of the LOI, the company and Cyclebit would become a combined entity, with the Cyclebit's existing equityholders rolling 100% of their equity into the combined public company. The company expects to announce additional details regarding the proposed business combination when a definitive agreement is executed, which is expected in the fourth quarter of 2022. No assurances can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transaction will be consummated on the terms or timeframe currently contemplated, or at all. Any transaction would be subject to board and equityholder approval of both companies, regulatory approvals and other customary conditions.

16:28 EDT CEO of Sunrun joined the President to celebrate Inflation Reduction Act passage - Mary Powell, CEO of Sunrun joined President Joe Biden at The White House to celebrate the passage of the historic Inflation Reduction Act , which invests $369B billion to fight climate change. During her visit, Powell spoke alongside other industry leaders, where she discussed the importance of clean home-based energy systems to fortify the nation's grid and more affordably and resiliently respond to climate change. She also addressed the impact the IRA will have on the growing demand for rooftop solar, battery storage and electric vehicles as extreme weather threatens the grid and home electricity rates surge to nearly 16% higher than last year. Powell highlighted how Americans can find relief from inflation by taking advantage of programs and incentives in the IRA to switch to cleaner, cheaper solar energy, home heating, cooking, and vehicle technology, which can save households up to $1,800 per year"We are seeing an unprecedented rise in energy inflation, wildfires, heat waves and freezing temperatures, and they are all creating demand for rooftop solar and battery storage," Powell said. "I applaud the passage of the Inflation Reduction Act because it drastically increases access to clean, reliable, and, in particular, affordable sources of energy. American families can now take advantage of new tax incentives for home solar, batteries, heating, electric vehicles and so much more. It's a huge win for the American people."

16:21 EDT Genfit announces FDA grants ODD for ezurpimtrostat to treat cholangiocarcinoma - Genfit announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to GNS5611, ezurpimtrostat, a novel clinical-stage autophagy/PPT1 inhibitor, for the treatment of cholangiocarcinoma. Cholangiocarcinoma is a rare liver malignancy with high mortality and limited treatment options. It occurs mostly in people over the age of 50

16:15 EDT Aditx Therapeutics announces 1-for-50 reverse stock split - Aditxt "announced that it will effect a 1-for-50 reverse split of its common stock effective as of 4:01 p.m. Eastern Time on September 13, 2022. Commencing with the opening of trading on The Nasdaq Capital Market on September 14, 2022, the Company's common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company's stockholders at the special meeting held on September 7, 2022, with the final ratio determined by the Company's board of directors."

16:08 EDT CatchMark Timber stockholders approve merger with subsidiary of PotlatchDeltic - CatchMark Timber Trust (CTT) announced that, at the special meeting, its stockholders approved the merger of CatchMark with and into a wholly owned subsidiary of PotlatchDeltic (PCH), pursuant to the terms of the Agreement and Plan of Merger, dated as of May 29. CatchMark will provide final vote results for the Special Meeting, as certified by the independent Inspector of Election, on a Form 8-K to be filed with the SEC. The transaction is expected to close on or about September 14, subject to the satisfaction or waiver of customary closing conditions. Under the terms of the Merger Agreement, among other things, each share of CatchMark Class A common stock, par value 1c per share issued and outstanding immediately prior to the effective time of the Company merger will be automatically converted into the right to receive, in accordance with the terms of the Merger Agreement, 0.230 validly issued, fully paid and non-assessable shares of PotlatchDeltic, without interest, plus the right to receive cash in lieu of fractional shares. Upon the closing of the transaction, CatchMark common stock will no longer be listed on any public market. King & Spalding and Venable served as CatchMark's legal counsel and Stifel, Nicolaus & Company, Incorporated acted as CatchMark's financial advisors. Perkins Coie and Skadden, Arps, Slate, Meagher & Flom served as PotlatchDeltic's legal counsel. Bank of America served as financial advisor to PotlatchDeltic.

16:07 EDT Great Panther Silver trading halted, news pending

16:06 EDT BWX Technologies submits Tc-99m generator NDA to FDA - The company states: "BWX Technologies announced that subsidiary BWXT Medical Ltd. has submitted a new drug application to the U.S. Food and Drug Administration to request approval of its technetium-99m generator for diagnostic imaging. Once approved for commercial production by regulatory bodies, BWXT Medical's new proprietary manufacturing technology will be used to irradiate molybdenum targets at an Ontario Power Generation reactor, process Mo-99 and subsequently incorporate material into Tc-99m generators at BWXT Medical's Kanata, Ontario facility for delivery to radiopharmacies and hospitals across the United States and Canada. Tc-99m is used in over 40 million diagnostic procedures annually, and is the daughter isotope of molybdenum-99. Historically Mo-99 has been produced within research reactors using uranium as a starting material. Alternatively, the BWXT Tc-99m generator will be produced from natural molybdenum targets irradiated at a commercial power reactor, greatly reducing complex waste by-products. These targets are processed into the finished active pharmaceutical ingredient and then loaded into generators that have the function and form of generators already used at radiopharmacies and hospitals today."

16:05 EDT McKesson names LeAnn Smith chief human resources officer - McKesson Corporation announced that LeAnn B. Smith has been selected to become executive vice president and chief human resources officer. Smith will succeed Tracy L. Faber, McKesson's current CHRO, who will be retiring after an accomplished 11-year tenure with McKesson. These changes are expected to be effective December 1, 2022. In her new role, Smith will report to Brian Tyler, chief executive officer, and serve as a member of the executive operating team. As McKesson continues to focus on people and culture as a strategic priority, Smith will have responsibility for all human resources disciplines, including attracting, developing and retaining talent across the company, championing employee diversity and inclusion initiatives, and leading transformational change. "McKesson is committed to developing talent at all levels of the organization and we are pleased to promote LeAnn to the role of chief human resources officer," said Brian Tyler, CEO, McKesson. "In this dynamic time, we look forward to benefitting from her more than 20 years of experience as McKesson continues to address the changing needs of our employees, foster a diverse and inclusive culture and become the best place to work in healthcare."

15:34 EDT Coinbase says fix being implemented for issue of trades intermittently failing - Coinbase said in a status post about reports of trades intermittently failing: "The issue has been identified and a fix is being implemented." Reference Link

15:14 EDT Bitcoin price down about 10% to trade near $20,000 - As of time of writing, bitcoin is down about 10% on a 24-hour basis to $20,120 in U.S. dollars, according to TradeBlock. Stocks levered to bitcoin prices include Bit Digital (BTBT), Riot Blockchain (RIOT), Marathon Digital (MARA), MicroStrategy (MSTR) and Coinbase Global (COIN).

15:01 EDT Weyerhaeuser reports work stoppage in Oregon and Washington as workers strike - Weyerhaeuser announced that as of this morning a work stoppage involving members of the International Association of Machinists and Aerospace Workers union is impacting its operations in Oregon and Washington. Weyerhaeuser has approximately 1,200 employees who are members of IAM, including employees in the company's Wood Products and Timberlands organizations."We have been formally engaged in collective bargaining with IAM since May, and we have made several offers related to wages and benefits," says Denise Merle, senior vice president and chief administration officer for Weyerhaeuser. "After we presented our final offer, IAM workers at multiple sites went on strike late last night. While we are very disappointed in their decision to walk out, we are committed to supporting our employees and negotiating in good faith with union representatives. We are prepared to continue discussions to produce a contract that is beneficial for employees and sustainable for the company across business cycles." Weyerhaeuser will continue working closely with customers and other partners in the region to minimize supply disruptions.

14:47 EDT Starbucks sees international store portfolio growth of over 30% - "Over the next three years, the international segment will deliver growth of international store portfolio by more than 30% to get us to over 25,000 international stores, system sales growth of nearly 40$ and profits that wee more than double, Starbucks said during the company's Investor Day.

14:16 EDT Funko targets organic revenue growth of over $2B by 2026 - Sees roughly 20% DTC net sales CAGR by 2026. Sees roughly 20% international revenue CAGR by 2026. Sees adjusted EBITDA margin of roughly 20% by 2026. Sees high-single digit to low double-digit net sales growth in core collectibles by 2026. Guidance taken from Investor Day presentation slides.

13:56 EDT NIST, Google to create new chip supply for researchers, tech startups - Yesterday, the U.S. Department of Commerce's National Institute of Standards and Technology said it signed a cooperative research and development agreement with Google (GOOGL) to develop and produce chips that researchers can use to develop new nanotechnology and semiconductor devices. The chips will be manufactured by SkyWater Technology (SKYT) at its Bloomington, Minnesota, semiconductor foundry. Google will pay the initial cost of setting up production and will subsidize the first production run. NIST, with university research partners, will design the circuitry for the chips. The circuit designs will be open source, allowing academic and small business researchers to use the chips without restriction or licensing fees. "By creating a new and affordable domestic supply of chips for research and development, this collaboration aims to unleash the innovative potential of researchers and startups across the nation," said Under Secretary of Commerce for Standards and Technology and NIST Director Laurie E. Locascio. This collaboration was planned before the recent passage of the CHIPS Act, but, Locascio said, "This is a great example of how government, industry and academic researchers can work together to enhance U.S. leadership in this critically important industry." Reference Link

13:32 EDT Waste Management to buy controlling interest in Avangard Innovative's U.S. unit - WM announced that it has agreed to acquire a controlling interest in Avangard Innovative's U.S. business, which will operate as Natura PCR - an independent company expected to scale and grow recycling capacity to produce an estimated 400 million pounds per year of post-consumer resin, or PCR, in five years. "Through Natura PCR, WM expects to deliver new recycling capabilities for its customers and provide circular solutions for films and clear plastic wrap used commercially, such as plastic stretch wrap for pallets, furniture film, grocery bags and potentially shrink wrap around food and beverage containers," WM stated. "WM's controlling interest in Natura PCR positions us to grow and scale rapidly in the emerging PCR space. WM's core material supply capabilities, with the head start and knowledge provided by Avangard's U.S. business, will help Natura PCR quickly deliver circular options to WM's customers as an important component of our continued growth strategy in recycling. Today, there is so much untapped potential to reuse film - which impacts many of our commercial customers. We can help our customers close the loop and bring more recycled materials to the store shelf," said Jim Fish, president and CEO, WM. Natura PCR plans to grow recycling capabilities at Avangard's existing plant in Waller, Texas, and build new plant capacity in the Midwest. Natura PCR will be primarily owned and controlled by WM. Avangard and affiliated entities will hold a collective minority equity position in Natura PCR. WM expects to receive investment returns comparable to its previously announced automation investments in single-stream recycling. The transaction is expected to close in late 2022, subject to the satisfaction of customary closing conditions, including regulatory approvals.

13:18 EDT John Culver stepping down as Starbucks COO by end of September - John Culver said during Starbucks' Investor Day that it will step down as the company's Chief Operating Officer "at the end of this month."

13:13 EDT Starbucks sees about 40% revenue growth in North America over next 3 years - Sees opening about 2 new stores per day in North America over the next three years and sees "progressive margin expansion" in the region, the company stated in slides presented by John Culver, group president, North America and chief operating officer, at the company's 2022 Investor Day.

12:59 EDT Starbucks sees net new store growth of 3%-4% annually in U.S. over next 3 years - Guidance from slides presented by John Culver, group president, North America and chief operating officer, at the company's 2022 Investor Day. Reference Link

12:29 EDT Uber pays NJ $100M for improperly classifying independent contractors - Uber Technologies and a subsidiary have submitted a $100M payment to the New Jersey Department of Labor and Workforce Development's Unemployment Trust Fund after an audit found the companies "improperly classified hundreds of thousands of drivers as independent contractors, depriving them of crucial safety-net benefits such as unemployment, temporary disability and family leave insurance, and failed to make required contributions toward unemployment, temporary disability and workforce development." The payment follows NJDOL audits that assessed Uber and its subsidiary Rasier a combined $78M in past-due contributions plus penalties and interest of $22M. Reference Link

12:06 EDT IMAX appoints Michele Golden as global CPO - IMAX Corporation named Michele Golden as its Global Chief People Officer, a role in which she'll oversee human resources, recruiting, talent management, and diversity, equity, & inclusion for the global entertainment technology company. Golden joins IMAX from WarnerMedia where she served most recently as its Chief Human Resources Officer for HBO Max, the culmination of a more than twenty-year career with the media and entertainment giant. Golden will report directly to IMAX CEO Rich Gelfond and Chief Legal Officer Rob Lister and be based in the Company's New York office.

12:03 EDT EDF Renewables North America signs VPPA with McDonald's - EDF Renewables North America announced a 15-year virtual power purchase agreement with McDonald's. The 255 MWac / 332 MWdc Apollo Solar project will help McDonald's to meet its sustainability goals and advance its commitment to climate action. Apollo Solar, located in Texas, is expected to begin delivery of low carbon electricity in June 2024. Approximately 300 jobs are expected to be created during the 2023-2024 construction phase with more than $30M generated in new tax revenue over the operating life for taxing entities. Apollo Solar will produce clean energy while minimizing impacts to wildlife, habitat, and other environmental resources.

12:00 EDT Innovid falls -13.4% - Innovid is down -13.4%, or -48c to $3.11.

12:00 EDT Web Street, Inc. rises 14.3% - Web Street, Inc. is up 14.3%, or $4.16 to $33.27.

12:00 EDT Planet Labs rises 14.9% - Planet Labs is up 14.9%, or 81c to $6.22.

11:33 EDT Golden Path Acquisition Corp trading halted, volatility trading pause

11:12 EDT Boeing reports 30 commercial airplane gross orders, 35 deliveries in August - In a post on its corporate site, Boeing reported 30 commercial airplane gross orders for August and 35 airplane deliveries last month. Reference Link

11:10 EDT Sunniva says Tribunal issues Interim Award denying relief requested by CPL - Sunniva announces that on September 7, 2022, the Company's subsidiary, CP Logistics received a interim ruling from JAMS Arbitration regarding the arbitration CPL commenced against the current owner and landlord of the California glasshouse, Bobs in regards to CPL's rights as tenant under an October 20, 2017 Conditional Build to Suit Lease and a March 2018 Subordinated Non-Disturbance and Attornment Agreement. The Tribunal issued an Interim Award denying the relief requested by CPL, finding CPL had breached the Lease, and thus was not entitled to specific performance. The Tribunal further granted, in part, Bobs' counterclaim for money damages and found Bobs was entitled to an award in the approximate amount of $8.6M and Bobs' attorneys fees. The precise amount of damages and fees awarded are subject to further proceedings that will be the subject of a Final Award. CPL is exploring its options. No decision has been made at this time on future steps.

10:46 EDT Twitter begins rolling out podcasts to Blue subscribers - In a Monday tweet, Twitter Blue said, "listen up: podcasts are coming to Twitter! now available in Twitter Blue Labs-members on iOS get early access to try the redesigned @TwitterSpaces tab, which includes podcasts, themed audio stations, and live + recorded Spaces (Android coming soon!)". Reference Link

10:14 EDT Citron Research sees Google as potential Pinterest acquirer - Andrew Left's Citron Research said via Twitter, "$PINS + $GOOG Dont look now but look who has the hottest property on social media. Shuffles by Pinterest.... when looking at the facts, it is obvious why Google will probably be a potential acquirer in the near future." Reference Link

10:10 EDT Ventoux CCM Acquisition Corp trading halted, volatility trading pause

10:04 EDT Gato Investments completes acquisition of Hemisphere Media - Gato Investments announced the completion of Gato's acquisition of Hemisphere. The transaction was previously announced on May 9, 2022, and approved by Hemisphere's stockholders at the Special Meeting of Stockholders held on September 8, 2022. Subject to the terms of the definitive merger agreement, Hemisphere stockholders will receive $7.00 per share of Class A Common Stock or Class B Common Stock. Hemisphere's common stock has ceased trading and will be delisted from the Nasdaq stock market.

10:02 EDT Worksport nears completion of tooling for COR portable energy storage system - Worksport is announcing it is nearing the completion of tooling for its COR portable energy storage system. This is the final step in a long effort to perfect the product and prepare it for market launch. COR, with modular batteries and advanced hot-swap technology, works with SOLIS, Worksport's groundbreaking advanced truck bed tonneau cover with integrated solar panels.

10:00 EDT Unity falls -11.3% - Unity is down -11.3%, or -$4.80 to $37.51.

10:00 EDT Planet Labs rises 10.7% - Planet Labs is up 10.7%, or 58c to $6.00.

10:00 EDT Web Street, Inc. rises 12.3% - Web Street, Inc. is up 12.3%, or $3.59 to $32.70.

09:49 EDT Avantor says 'continues to perform well across end markets' - Avantor said in a regulatory filing, "The Company also reiterated that it continues to perform well across end markets and geographies, delivering approximately 7% core organic net sales growth, greater than 140 basis points of Adjusted EBITDA margin expansion, and 13% growth in adjusted net income in the first half of 2022, all of which are at the high end or above the Company's long-term target ranges."

09:47 EDT AEA-Bridges Impact Corp. falls -8.5% - AEA-Bridges Impact Corp. is down -8.5%, or -85c to $9.15.

09:47 EDT Carvana falls -10.5% - Carvana is down -10.5%, or -$4.42 to $37.86.

09:47 EDT Planet Labs rises 10.7% - Planet Labs is up 10.7%, or 58c to $6.00.

09:46 EDT NeuroBo Pharmaceuticals trading resumes

09:40 EDT Truist Financial sees expenses higher in 2023 vs. 2022, says CEO - CEO William Rogers says Truist is "committed" to positive operating leverage and positive PPNR growth. Comments taken from the Barclays Global Financial Services Conference.

09:37 EDT Delwinds Insurance Acquisition to transfer listing to NYSE American - Delwinds Insurance Acquisition Corp. announced that it will transfer its listing from The New York Stock Exchange to the NYSE American. In connection with listing on NYSE American, Delwinds will voluntarily delist from the NYSE. Following the expected consummation of the previously announced business combination between Delwinds and FOXO Technologies, the Class A Common Stock and Warrants of the combined company are expected to begin trading on NYSE American under the symbols "FOXO" and "FOXO WS," respectively, on or around September 16, subject to the business combination being approved by the stockholders of Delwinds and FOXO, respectively, and the satisfaction or waiver of other closing conditions. Until the business combination is complete, Delwinds' Class A Common Stock, Warrants, and units will continue to trade under the ticker symbols "DWIN," "DWIN WS," and "DWIN U," respectively, on the NYSE.

09:35 EDT NeuroBo Pharmaceuticals trading halted, volatility trading pause

09:34 EDT TC Biopharm approved by MHRA to apply 18-month shelf-life to OmnImmune - TC Biopharm announced that it has received approval from the U.K. regulatory body, MHRA, to apply an 18-month extrapolated shelf life to its current allogeneic cell therapy product, OmnImmune. "This award enables TC BioPharm to ship and store sufficient product which can then be held cryopreserved at clinical sites to fulfill the requirements not only for its current Advanced Myeloid Leukemia trial ACHIEVE, but also for future clinical trials and eventually commercial treatment of patients. Additionally, TC BioPharm's in-house quality control department will continue to gather data in order to extend the shelf-life of OmnImmune," the company stated.

09:31 EDT Nymox in process of preparing FDA requested documentation for NDA resubmission - Nymox Pharmaceutical provided a current update on business developments, stating: "The company has corresponded with and has met with the FDA during the past few months. The agency has provided very helpful feedback to the company. FDA has specified what additional information is required in resubmission of the NDA; and the company is in the process of preparing the requested documentation for the resubmission of requested data, and for further interactions with FDA for additional guidance. The company expects to submit a marketing application for Fexapotide in Europe in the upcoming 4th quarter of this year and will provide further information as the time for the Fexapotide submission approaches in the near future." Paul Averback, CEO of Nymox, added: "We are very fortunate to have the benefit of expert advisors both in the US and in Europe who have greatly contributed to the overall project. In addition, the authorities have provided consistently helpful feedback. The company and its extended team are working constantly to make sure that no stone is left unturned to help this remarkable new treatment become available for the vast number of men who are in need of safer more effective choices to manage their bothersome and distressing lower urinary tract BPH symptoms."

09:20 EDT Stabilis Energy provides LNG bunkering services for ship in Long Beach, CA - Stabilis Solutions recently completed the first bunkering of liquefied natural gas for Pasha Hawaii's newest container ship MV George III in Long Beach, CA. In partnership with West Coast Clean Fuels, Stabilis provided project development, management, engineering, technical and operational services.

09:18 EDT RocketFuel Blockchain partners with PaymentCloud - RocketFuel Blockchain announces its partnership with merchant services provider PaymentCloud. Peter Jensen, Chief Executive Officer of RocketFuel, commented, "We are excited to work closely with PaymentCloud as they realize the benefits of utilizing blockchain technologies for e-Commerce payments and check-out solutions and our "Pay with Crypto" solution. PaymentCloud's personalized approach sets it apart from other payment processors regarding its relationships with its merchants. In just a short time, we have already gone live with 15 of their 20 merchants that have signed. Our super-fast processing power, real-time payment options, and secure and stable transactions are a huge value-add to PaymentCloud merchants."

09:15 EDT Stabilis gives technical & operational LNG services for LNG-powered ship in CA - Stabilis Solutions recently completed the first bunkering of liquefied natural gas for Pasha Hawaii's newest container ship MV George III in Long Beach, CA. In partnership with West Coast Clean Fuels, , Stabilis provided project development, management, engineering, technical and operational services."Pasha's leadership in lowering shipping emissions on West Coast shipping routes is a significant step toward the improvement of the air quality in the region," commented Westy Ballard, President & CEO of Stabilis, "and we are delighted to have partnered with WCCF to play a part."Ballard further commented, "The Port of Long Beach is an important international trading hub for the U.S., and we look forward to working diligently with the Port and our customers to further advance the lowering of emissions in ocean shipping." Pasha Hawaii's MV George III is a 774-foot container ship operating between Long Beach, CA, Honolulu, HI, and Oakland CA and is currently scheduled to bunker every second week at the Port of Long Beach. The vessel is the first of three LNG-powered ships that Pasha is putting into service with the second, the Janet Marie, expected in late 2022 and the third expected to be deployed in mid-2023.

09:14 EDT Stereotaxis announces OPRMC is establishing its second robotic program - Stereotaxis announced that Overland Park Regional Medical Center, OPRMC, is establishing its second robotic program for the treatment of heart rhythm disorders. OPRMC is now among the first in the nation to adopt the Genesis Robotic Magnetic Navigation system, the latest advance in robotic technology and will become the first hospital in the U.S. to double its capacity for robotic cardiac ablation with two Stereotaxis systems for patients receiving minimally invasive cardiac ablation procedures. "We are delighted to expand our partnership with Dr. Lakkireddy and Overland Park Regional Medical Center as they improve patient care, advance clinical science, and continue to grow a leading arrhythmia care program in Kansas City," said David Fischel, Chairman and CEO of Stereotaxis.

09:12 EDT Varonis announces force multiplier for Salesforce admins - Varonis Systems announced a force multiplier for Salesforce admins - one-click permissions comparison and analysis. These new features strengthen Varonis' Salesforce security and compliance solution, which helps customers identify risky misconfigurations, discover sensitive data, and detect internal and external threats to SaaS data.

09:11 EDT Amazon introduces next generation Kindle - Amazon announced the next generation of Kindle-the lightest and smallest Kindle. Starting at just $99.99, the new Kindle includes a 300 ppi high-resolution six-inch display, USB-C charging, longer battery life of up to six weeks, and room for thousands of books with twice the storage. The same features also come with Kindle Kids, which includes a one-year subscription to Amazon Kids+ that provides kids with unlimited access to thousands of kid-appropriate books. Kindle and Kindle Kids pre-orders start today and will begin shipping October 12.

09:10 EDT Verisk announces expanded integration of 360Value on Duck Creek platform - Verisk (VRSK) announced the expanded integration of its 360Value replacement cost estimates on Duck Creek's (DCT) Content Exchange. At a time when supply chain delays and inflation are rapidly changing reconstruction costs, the addition of 360Value for Personal Property will enable homeowners insurers to access localized, continually refreshed data on materials and labor costs from Verisk through the Duck Creek Platform. "Quick and easy access to reliable replacement cost estimates is super critical for homeowners insurers in today's volatile market," said Rohit Bedi, Chief Revenue Officer, Duck Creek. "With the out-of-box integration of Verisk's 360Value into the Duck Creek Content Exchange, carriers who use our software will now be able to make faster and more informed underwriting decisions throughout the policy life cycle."

09:08 EDT Latch announce collaboration with WeWork - Latch (LTCH) announced that it is collaborating with WeWork (WE) to provide residents of Latch-enabled multifamily buildings in New York City with WeWork All Access memberships. Through this collaboration, Latch residents will be able to opt-in to WeWork All Access, unlocking access to WeWork's global portfolio of flexible office space. The partnership between WeWork and Latch is the first of its kind for these brands, and reflects the growing demand from workers residing in apartments to have access to a third workspace between the home and office. The program will be available at select apartment buildings in New York City, with plans to expand throughout the metro area and, eventually, nationwide. "Residents want more flexible relationships with their physical spaces that meet their ever-changing needs and improve their lives. At Latch, we're focused on creating new experiences that provide this flexibility in innovative ways," said Luke Schoenfelder, Latch Co-Founder, CEO, and Chairman of the Board of Directors. "We're thrilled to partner with WeWork to help expand the way people think about their space as it relates to work, and enable multifamily building owners to better differentiate their properties to attract renters."

09:07 EDT Rubicon Technologies teams with Samsara - Rubicon Technologies (RBT) announced that it has entered a technology partnership with Samsara (IOT), to unlock new value for shared municipal customers. Together, Rubicon and Samsara's complementary technology suites will help enable heavy-duty municipal fleet operations to optimize routes and citizen services, which will improve efficiency, empower drivers, lock in community safety gains, and save tax-payer dollars. Samsara is the pioneer of the Connected Operations Cloud, built to access, analyze, and act on the world's vast expanse of operations data. Thousands of customers spanning transportation, government, food and beverage, and more use mission-critical insights from Samsara to shape their operations. Streamlined data sharing made possible by Samsara's open API provides customers with a single source of truth to improve efficiency, reduce costs, and maintain operational resilience.

09:06 EDT C3.ai expands partnership with Google Cloud - C3 AI (AI) and Google Cloud (GOOG) announced the three-year expansion of their partnership to significantly accelerate their joint selling and co-development efforts. C3 AI's entire portfolio of enterprise AI applications is available on Google Cloud. Under the terms of the new partnership, the two companies will scale their joint go-to-market strategy and expand their joint customer pilot programs with Fortune 2000 companies. C3 AI and Google Cloud will also co-develop new AI-driven applications, using Google Cloud's Vertex AI, ML capabilities, and data analytics services. In addition to industry-first enterprise AI software products, all of C3 AI's 42 turnkey enterprise AI applications have been optimized for Google Cloud and are available on the Google Cloud marketplace.

09:05 EDT Sermonix Pharmaceuticals announces results of Phase 2 study of lasofoxifene - Sermonix Pharmaceuticals announced results of its signal-seeking Evaluation of Lasofoxifene in ESR1 Mutations Phase 2 study. The results were initially shared Sept. 10 during a late-breaking oral presentation at the European Society for Medical Oncology Congress 2022 in Paris. The open-label ELAINE 1 study began U.S. enrollment in September 2019, assessing the efficacy and safety of oral lasofoxifene versus intramuscular fulvestrant, a selective estrogen receptor degrader, in 103 patients. All participants were post-CDK4/6 inhibitor/aromatase inhibitor therapy and had an ESR1 mutation. Progression-free survival was the primary endpoint. Top-line data included: Median progression-free survival was 6.04 mos. for lasofoxifene vs. 4.04 mos. for fulvestrant. Clinical benefit rate was 36.5% for lasofoxifene vs. 21.6% for fulvestrant. CBR is defined as the percentage of all subjects with a complete or partial response; or stable disease for greater than/= 24 weeks. Objective response rate was 13.2% for lasofoxifene vs. 2.9% for fulvestrant, with 1 confirmed complete response and 4 confirmed partial responses in the lasofoxifene arm vs. 1 PR in the fulvestrant arm. PFS was numerically and consistently greater with lasofoxifene vs. fulvestrant when visceral metastasis and/or Y537S ESR1 mutation subgroups were analyzed. While not reaching statistical significance in this 103-patient study, all endpoints numerically favored lasofoxifene. Exploratory endpoints included: PFS at 6 mos. for lasofoxifene was 53.4% vs. 37.9% for fulvestrant; PFS at 12 mos. was 30.7% for lasofoxifene vs. 14.1% for fulvestrant. Clearance of ctDNA also favored lasofoxifene over fulvestrant. Most common adverse events were fatigue, nausea, arthralgias and hot flashes; most were Grade 1/2. No thrombotic events occurred. "Sermonix is pleased with the outcomes reported in our ELAINE 1 trial comparing lasofoxifene with fulvestrant, suggesting lasofoxifene's anti-tumor activity and potential to play a critical role in the targeted precision medicine treatment of ESR1-mutated advanced ER+ breast cancer," said Dr. David Portman, Sermonix founder and chief executive officer. "Lasofoxifene following endocrine/CDK4/6 inhibitor therapies continues to be studied and we anticipate efficacy will be confirmed in a larger clinical study. Sermonix is planning a Phase 3 registrational combination study based on these results as well as encouraging efficacy and safety demonstrated in the ELAINE 2 study of lasofoxifene and abemaciclib reported at this year's ASCO annual meeting." Lasofoxifene is an investigational, nonsteroidal selective estrogen receptor modulator (SERM), which Sermonix licensed globally from Ligand Pharmaceuticals.

09:05 EDT Sprout Social, Salesforce extend partnership with Service Cloud integration - Sprout Social (SPT) announced a new integration with Salesforce Service Cloud (CRM) to provide brands with a 360-degree view of their customer interactions. Earlier this year, Sprout Social and Salesforce launched a global partnership which made Sprout the preferred social media management solution for Salesforce customers. Building upon that partnership, the new Service Cloud integration ensures Salesforce customers can manage all of their social customer care requests directly from within Service Cloud while enriching customer CRM profiles with social data to provide a holistic view of customer interactions. This functionality becomes increasingly important as service organizations rank social media the #1 non-traditional channel they use for customer support. In addition to the Service Cloud functionality, Sprout will also integrate Marketing Cloud Intelligence-Salesforce's marketing analytics solution-into its platform to provide an automated method for bringing social data and insights into overall marketing dashboards in Salesforce and Intelligence.

09:03 EDT Usio announces passing of chairman, co-founder Michael Long - Usio announced the loss of Michael Long, the company's chairman and co-founder, who passed away on September 7.

09:02 EDT Corteva authorizes $2B share repurchase program - Corteva authorized a new $2B share repurchase program. The authorization is immediately effective, does not expire, and gives management discretion in determining the conditions under which shares may be purchased. This newly authorized program is in addition to the company's existing $1.5B program announced in August 2021, which had $650M remaining as of June 30, 2022.

08:52 EDT Energy Recovery releases annual ESG report - Energy Recovery released its annual Environmental, Social, and Governance report this week, underscoring the strong connection between the company's business goals and its sustainability efforts. This ESG report also showcases the company's commitment to transparency, offering a comprehensive look at progress against its ESG goals. Energy Recovery uses its PX technology to reduce energy costs and emissions in critical industries such as desalination, industrial wastewater treatment, and CO2 refrigeration. The report features examples of customers' use of PX technology in various industries, illustrating how PX-based products can help customers adapt to increasingly stringent global environmental regulations while reducing costs. "By lowering energy consumption for our customers, we've been making sustainability affordable since our company's inception 30 years ago. Even though we're pleased with our progress to date, we are always looking to improve and are confident in our ability to continue delivering transformational products that improve sustainability and lower costs. Our ESG goals are designed to help us deliver on this vision and are aligned with strategic imperatives for our business, including fostering innovation, workforce development, and reducing climate impacts," said Robert Mao, Chairman of the Board, President, and CEO of Energy Recovery.

08:49 EDT Mill City Ventures III funds $840,000 short-term insurance settlement - Mill City Ventures III announced its funding of a settled insurance claim in the amount of $840,000. The related short-term note is expected to mature in 120 days with a payback of $933,334, representing an annualized return of 33.33%.

08:49 EDT Recruiter.com announces Recruiter.com Shortlist - Recruiter.com Group is pleased to announce Recruiter.com Shortlist. Designed to make the hiring process more manageable, Recruiter.com Shortlist identifies highly qualified, engaged candidates and compiles a shortlist of ten hand-selected candidates to pass along to the company looking for talent. Recruiter.com Shortlist eliminates hours spent speaking with prospective candidates to find out if they are qualified for the role and the extra cost spent on an expensive headhunter.

08:47 EDT SaverOne 2014 installs 10 SaverOne systems on Novolog delivery trucks - SaverOne 2014 announced that SaverOne has penetrated the pharmaceutical delivery vertical, installing an initial 10 SaverOne systems on Novolog delivery trucks. The potential is hundreds of delivery trucks in Israel. Novolog is a leading Israeli healthcare company, with a focus on pharmaceutical and medical device distribution and logistics.

08:47 EDT CACI awarded $123.4M NIWC task order - CACI announced that it was awarded a $123.4M task order to continue to provide the Naval Information Warfare Center, or NIWC, Atlantic with defense health readiness engineering support for the U.S. Navy, U.S. Marine Corps, and U.S. Air Force. The five-year task order was awarded under the Seaport-Next Generation contract vehicle.

08:44 EDT Real Good Food launches Asian Entrees platform - The Real Good Food Company announced the launch of its newest platform, Asian Entrees, including, Orange Chicken, General Tso's and Sweet & Sour. Real Good Foods' Asian Entrees are currently available at Walmart, Stop & Shop, Stater Bros, Safeway Albertsons, as well as available direct to customers on realgoodfoods.com.

08:43 EDT AmpliTech Group engages PCG Advisory for investor relations - AmpliTech Group announced that it has retained PCG Advisory to serve as an advisor for investor relations and strategic communications.

08:42 EDT Cellectar announces publication of data from its Phase 2 CLOVER-1 study - Cellectar Biosciences announced the publication of a paper highlighting data from an expansion cohort of the ongoing Phase 2 CLOVER-1 study of iopofosine I-131 in relapsed/refractory B-cell malignancies in the September issue of Blood Cancer Journal, a peer-reviewed Nature journal. The paper, entitled "Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy," showed initial results from the expansion cohort of seven post anti-BCMA immunotherapy quad-class refractory relapsed/refractory multiple myeloma patients with a median of 9 prior therapies. Initial findings in the population receiving more or equal to 60 mCi total administered dose showed an overall response rate of 50% and a minimum of stable disease for all treated patients. At the time of data cutoff, while median overall survival had not been reached, the mean overall survival was 9.1 months. The safety was manageable, with no dosing delays, dose reductions, or treatment discontinuations caused by adverse events. The most common grade 3/4 adverse events were cytopenias, which is consistent with previous studies. "The 50% overall response rate in patients from this expansion cohort who had received and failed an average of 9 lines of prior treatment, including many of the newer anti-BCMA therapies, CAR T-cell therapies, bispecific antibodies and antibody drug conjugates is impressive," said James Caruso, president and CEO of Cellectar. "We believe these findings along with data from previous clinical studies demonstrate the potential of iopofosine to broadly treat patients with aggressive hematologic cancers, like multiple myeloma, and less aggressive cancers, like Waldenstrom's macroglobulinemia, which is currently under evaluation in our WAM Clover-1 pivotal study."

08:41 EDT Save Foods says transformation to commercialization continues to accelerate - Save Foods issued a letter to shareholders, which read in part, "Save Foods' transformation from R&D to commercialization continues to accelerate, and on behalf of our entire team, we want to thank our valued stockholders for their continued support as we continue to execute on our mission to deliver solutions that empower and assist growers, packers and food retailers in their efforts to reduce their waste and increase revenue. Prior to our up-list to Nasdaq just over one year ago in May 2021, we were an R&D company introducing our first treatment for citrus fruit. As of today, we are now serving customers with product offerings that treat avocados, mangos, pears, dates, bell peppers and blueberries. Likewise, to address the rapidly growing demand for these product offerings, we have expanded our operational footprint worldwide by more than doubling our team, including the addition of seven new representative offices in key exporting countries. For those that have been following our transformation, you likely have noticed an increased pace of pilot program announcements. We now have more than 60 active pilot programs underway in 12 regions around the world and we expect this number to increase. We believe this growth, in a traditionally conservative industry resistant to change,signals that we are heading in an exciting direction that we anticipate to translate into revenue growth beginning in the fourth quarter of 2022 as the citrus season in the northern hemisphere gets underway in the coming months...With a wealth of opportunities ahead and our operational momentum increasing, we completed a follow-on offering in August 2022 to further support our near-term growth initiatives. We believe this funding will help to ensure the continued acceleration of our growth and market expansion as we seek to convert our growing number of active pilot programs into commercial sales. Save Foods presents a unique green treatment that could efficiently replace the various hazardous chemicals used today in our food supply chain and at the same time address both food waste and food safety. We are helping growers, packers, and food retailers to minimize waste, maximize supply chain efficiencies, increase their revenues and extend their market reach while delivering superior quality fruits and vegetables, and in doing so, we believe we can create significant stockholder value. We are just getting started in this exciting and massive market opportunity and look forward to sharing our continued successes with you as we execute on our mission of reducing food waste and ensuring food safety."

08:40 EDT Wells Fargo sees 2-3 new credit card products over the next year, CFO says

08:39 EDT Manhattan Associates helps Floor & Decor unify its supply chain - Manhattan Associates announced that Floor & Decor has chosen to upgrade its existing Manhattan solutions to Manhattan Active Supply Chain. This decision provides Floor & Decor with enterprise-wide supply chain unification via the most modern cloud-native software infrastructure available. With over 174 warehouse store locations in the US, Floor & Decor is a specialty retailer of hard surface flooring and related accessories. "Making the transition to the Manhattan Active suite of solutions will further enhance and simplify Floor & Decor's supply chain network," said Bob Howell, executive vice president, Americas at Manhattan. "Floor & Decor is currently experiencing tremendous success and supply chain growth and Manhattan Active solutions are built to scale and adapt to those changes."

08:38 EDT Quoin Pharmaceuticals establishes patient specific website for ongoing study - Quoin Pharmaceuticals has established a patient specific website to facilitate patient awareness and participation in its ongoing clinical study evaluating QRX003 for the treatment of Netherton Syndrome. The randomized, double blinded, vehicle-controlled study was initiated in June 2022 and will assess two different doses of Quoin's topical lotion, QRX003, versus a placebo lotion in Netherton patients. The test materials will be applied once daily over a twelve-week period, to pre-designated areas of the patient's body. Based on discussions with the FDA, a number of different clinical endpoints will be assessed in the study. Quoin CEO, Dr. Michael Myers, said, "As the pace of clinical trial site opening accelerates, we anticipate recruitment of patients in a timely manner. We believe the establishment of this patient specific website could be an effective tool to provide information about our clinical study and facilitate patient recruitment."

08:36 EDT KULR Technology receives DoT special permit for SafeCase solution - KULR Technology Group announced that it has received approval from the Department of Transportation to increase the energy levels in three special permits from 2.1 kWh to 2.5 kWh, expanding usage for its SafeCase product. KULR will utilize the permit upgrades to support a recently-awarded project with one of the three largest outdoor rider landscaping companies in the world for the safe shipment and storage of Li-Ion batteries. The permit approval restates the safety of KULR's SafeCase product for transportation and storage of Li-Ion batteries, and will enable the large landscaping equipment customer to safely transport its batteries for services or end of life on its new line of higher-capacity landscaping electric vehicles. In addition to this project, the permit upgrades are expected to generate expanded use cases for the SafeCase product with existing and new customers.

08:35 EDT Ambow Education wins bid for integrated circuit design for Chinese university - Ambow Education announced that one of its wholly-owned subsidiaries in China won its bid for Guizhou University's integrated circuit design and simulation platform project. The winning bid totaled RMB26.98M. The project will leverage talent training, industrial services, innovation, entrepreneurship and scientific research, and aim to take full advantage of the integration of industry and education to support and lead the development of the IC industry in the western region. The Guizhou University project is Ambow's third recent win of a university collaboration project.

08:33 EDT Envista announces data for NXP800 in a preclinical xenograft model - Nuvectis Pharma announced positive data for NXP800 in a preclinical xenograft model of ARID1a-mutated gastric carcinoma. "Following the strong preclinical proof of concept in ARID1a-mutated ovarian carcinoma models, we are very pleased with this new preclinical data for NXP800 in ARID1a-mutated gastric cancer, potentially expanding the development opportunity for NXP800 to an additional therapeutic area with a clear unmet need," said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis. Mr. Bentsur continued, "Out of approximately 26,000 people that receive a diagnosis of gastric cancer annually in the United States, it is estimated that about 20-25% have ARID1a-mutated tumors. Gastric cancer has a very poor prognosis with a 5-year survival rate limited to 32%. The NXP800 Phase 1a dose escalation study is progressing as planned and we expect to begin the Phase 1b portion of the study in Q1 2023." Key Results: The study was conducted in a mouse model of ARID1a-mutated gastric cancer. Mice in each group were treated with either vehicle or NXP800 and tumor volumes were measured over 28 days. Treatment with NX800 resulted in tumor regression and substantial tumor growth inhibition versus the control.

08:31 EDT T. Rowe Price reports preliminary AUM $1.34T at August 31 - Client transfers from mutual funds to other portfolios, including trusts and separate accounts, were $1.5B in August 2022 and $3B for the quarter-to-date period ended August 31, 2022. This brings total client transfers for the year-to-date period ended August 31, 2022, to $10B.

08:29 EDT XS Financial provides $13M capex lease facility to Connected - XS Financial announced that it has entered into a new lease agreement with Connected International, a vertically integrated California operator with additional operations in Florida and Arizona. Connected has been approved for a $13M CAPEX lease facility, with an immediate drawdown of over $4.4M for a sale-leaseback and to purchase equipment with up to 60-month terms. This equipment acquisition will enhance the capabilities of existing processing facilities and buildouts for their California and Arizona operations.

08:24 EDT ArrowMark Financial Corp. announces estimated NAV of $21.23 as of August 31 - ArrowMark Financial announced that the Company's estimated and unaudited Net Asset Value as of August 31, 2022, was $21.23. The NAV was up $0.13 per share from the prior month.

08:22 EDT Fresh Tracks initiates MAD portion of Phase 1 study of DYRK1A inhibitor FRTX-02 - Fresh Tracks Therapeutics announced that it has initiated the multiple ascending dose, MAD, portion of the ongoing Phase 1 clinical trial in Canada evaluating FRTX-02, the Company's lead drug candidate, in healthy adult subjects. "We are excited with the progress we are making in the first-in-human study of FRTX-02, particularly as we enter the MAD part of the trial on schedule and complete the SAD cohorts," commented Dr. Monica Luchi, Chief Medical Officer of Fresh Tracks Therapeutics. "We are encouraged that FRTX-02 has been safe and well tolerated thus far and remain on track to report Phase 1 SAD and MAD topline results by early 2023." The first-in-human Phase 1 trial of FRTX-02 is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of FRTX-02 capsules in both healthy adult subjects and patients with atopic dermatitis. Part 1A of the study is a single ascending dose assessment, which will enroll a total of 56 healthy volunteers in one of seven cohorts, each of which includes six subjects receiving a single dose of FRTX-02 and two subjects receiving a placebo. Part 1B of the study is a MAD assessment of FRTX-02 or placebo in healthy adult subjects. In the MAD assessment, 33 healthy volunteers will be enrolled in one of three cohorts made up of 11 subjects each, and the cohorts will include nine subjects who will receive FRTX-02 and two subjects who will receive a placebo, in each case once-daily for 14 days. After completing Part 1, the Company intends to initiate Part 2 of the study, which will compare FRTX-02 to placebo in patients with moderate-to-severe AD over 28 days of treatment and will also include a preliminary assessment of efficacy. The ongoing Phase 1 study of FRTX-02 marks the first time a DYRK1A inhibitor intended for patients with autoimmune diseases has been administered in humans.

08:20 EDT Eagle Bulk Shipping adds capacity, acquires modern Ultramax bulkcarrier - Eagle Bulk Shipping announced that it has expanded its fleet with the purchase of a high-specification 2015-built scrubber-fitted Ultramax bulkcarrier for USD 27.5M. The vessel, which was constructed at Imabari Shipbuilding in Japan, will be renamed the M/V Tokyo Eagle and deliver to the Company during the fourth quarter of 2022. As previously disclosed, the Company closed on the sale of the M/V Cardinal in August 2022. The vessel was sold for USD 15.8M and delivered just prior to her statutory drydock due date. Following these transactions, Eagle's fleet will total 53 ships with an average age of 9.5 years.

08:18 EDT TriLink BioTechnologies expands mRNA raw material offering - TriLink BioTechnologies has expanded its GMP-grade product offering to include N1-Methyl-Pseudouridine-5'-Triphosphate, a modified nucleoside-triphosphate essential for mRNA manufacturing. This new product extension leverages TriLink's quality systems and GMP capabilities, including cleanroom manufacturing, expanded analytical testing, and process verification. The demand for N1-Methyl-pseudouridine modified mRNA has risen significantly in the past several years due to its incorporation in both FDA-approved mRNA vaccines against COVID-19.

08:15 EDT Dyadic International provides update on recent scientific achievements - Dyadic International updates the market on recent scientific achievements. Dyadic's C1 protein production platform continues to be optimized in terms of speed to the clinic and increasing productivity of antigens, antibodies, and other therapeutic proteins. Dyadic recently developed new transformational technology and techniques which demonstrate significant breakthroughs in higher levels of yield production across different classes and types of proteins. In certain instances, by applying these genetic elements, the C1 platform has generated up to 9-10x greater productivity when compared to previous C1 cell lines developed in both the animal and human health markets. The following represents recent additional achievements with our C1 technology platform: In addition to the Company's DYAI-100 based Wuhan RBD vaccine, the Company has successfully expressed the following variants: Alfa, Beta, Gamma, Delta, and Omicron B.1.1.529 at 0.5-2.5 g/L levels, with Omicron BA.5 currently under development. A nine-fold improvement in the expression yield for Nivolumab, a potential monoclonal antibody for oncology expressed at 22.3 g/l in a seven-day fermentation. A recombinant animal health antigen has been expressed at up to 10 g/L in 7 days. A biologically active neuraminidase, a potential antigen for influenza, has been expressed at 0.8 g/L in 7 days for potential use in combination with Hemagglutinin to play an important role in providing broader influenza vaccine-induced protection. Mice trials conducted by Oslo University for NA, like the previously reported HA produced from C1-cells, generate high neutralizing antibody levels. A non-human primate study completed dosing of a C1 produced COVID-19 monoclonal antibody that has demonstrated broad neutralization and protection against Omicron and other variants of concern in hamsters. Full data readout is anticipated later this year, but to date data supports conducting a toxicology study and cGMP manufacturing for potential Phase 1 clinical trial to further demonstrate safety of C1 produced proteins in humans. Potential next generation pan coronavirus vaccine candidates: the Company expressed Wuhan and Omicron Ferritin S gRBD nanoparticle antigens; Wuhan S gRBD nanoparticle has been expressed at greater than 3 g/L in five days.

08:12 EDT AvePoint completes acquisition of tyGraph - AvePoint announced it completed its acquisition of tyGraph, which is a platform that allows organizations to organize, measure, and analyze human interactions to accelerate success in the digital workplace. "The acquisition of tyGraph complements AvePoint's Confidence platform by adding robust analytics capabilities that enable organizations to uncover workplace engagement insights to improve decision making, optimize performance, and positively impact how people work," the company said. "We are excited to welcome tyGraph to the AvePoint team in our mission to enable organizations to collaborate with confidence in the modern workplace," said Dr. Tianyi Jiang, Co-Founder and CEO, AvePoint. "As more companies invest in digital transformation to move faster, become more agile, reduce costs, and improve productivity, it is essential to have relevant insights to inform how they can facilitate sustainable adoption of their investments. The acquisition of tyGraph marks another important step in our commitment to bringing a robust, end-to-end experience to organizations building today's modern workplace."

08:11 EDT Kroger Precision Marketing activates omnichannel inventory through Magnite - Magnite (MGNI) announced it has been selected as one of the inaugural CTV platforms to support The Kroger Co.'s (KR) retail media advertising business, Kroger Precision Marketing, KPM. Working with Magnite, KPM will enable its first party data packaged with premium omnichannel inventory, with an emphasis on CTV but spanning all formats including display and online video. Magnite reaches 80 million CTV households in the US and 9 out of 10 viewers of ad-supported TV. The collaboration will enable advertisers to purchase CTV and video inventory enriched with KPM first party data through the buy-side tools of their choosing. "With people consuming more TV hours through connected devices, brands need access to retail sales data in the programmatic CTV environment," said Michael Schuh, VP of Media Strategy and Program Development at Kroger Precision Marketing. "We're excited to be working with Magnite to provide brands with a centralized access point to video and CTV inventory. We expect this collaboration will help solve for supply fragmentation and bring scale for CPG advertisers who are looking to activate on CTV."

08:10 EDT GE Healthcare, Lantheus announce flurpiridaz trial met co-primary endpoints - GE Healthcare (GE) and Lantheus (LNTH) have announced that the recent Phase III clinical trial of their investigational radiotracer, flurpiridaz, has met its co-primary endpoints of exceeding a 60% threshold for both sensitivity and specificity for detecting Coronary Artery Disease, or CAD. The findings, shared at the American Society of Nuclear Cardiology, or ASNC, Congress, in Florida, U.S., also demonstrate flurpiridaz Positron Emission Tomography, or PET, has higher diagnostic efficacy and image quality in patients with suspected CAD, compared with Single Photon Emission Computed Tomography, or SPECT, Myocardial Perfusion Imaging, or MPI, the predominant procedure used in nuclear cardiology. SPECT MPI represents approximately 6M procedures per year in the U.S. The Phase III Open-Label Study, which involved over 600 patients across sites in the U.S., Europe and Canada assessed the diagnostic efficacy of flurpiridaz in detecting CAD. If approved, this investigational agent would offer the advantages of 18F, with broad available distribution and a half-life of almost two hours, removing the need for it to be manufactured in the immediate vicinity of the imaging department. This longer half-life could also make Flurpiridaz Injection suitable for exercise stress testing, which is not feasible with existing cardiac PET radiotracers.

08:09 EDT aTyr Pharma receives FDA Fast Track designation for efzofitimod - aTyr Pharma announced that the U.S. Food and Drug Administration, FDA, has granted the company Fast Track designation for its lead therapeutic candidate, efzofitimod, for the treatment of systemic sclerosis-associated, interstitial lung disease, ILD. Efzofitimod is a first-in-class immunomodulator that downregulates innate and adaptive immune responses in uncontrolled inflammatory disease states via selective modulation of neuropilin-2. Clinical proof-of-concept was recently established for efzofitimod in a Phase 1b/2a study in patients with pulmonary sarcoidosis, a major form of ILD, and the company is currently investigating efzofitimod in patients with pulmonary sarcoidosis in a global Phase 3 study called EFZO-FI. "This Fast Track designation reflects the potential of efzofitimod to address a significant unmet need for patients with SSc- ILD, which is the leading cause of death in scleroderma patients," said Sanjay Shukla, M.D., M.S., President and CEO of aTyr. "As highlighted in the ILD sessions at the recent European Respiratory Society International Congress, it is clear that there is a need for more effective and safer therapies for fibrotic lung diseases, including sarcoidosis and ILD that results from scleroderma. We believe this designation further validates efzofitimod and greatly expands the market potential for this first-in-class therapeutic."

08:08 EDT Cidara initiates Phase 2a human viral challenge trial to evaluate CD388 - Cidara Therapeutics (CDTX) announced the initiation of its Phase 2a trial to evaluate the pre-exposure prophylactic activity of CD388 against influenza virus. CD388 is a highly potent, long-acting antiviral designed to deliver universal prevention of seasonal and pandemic influenza. The study is being conducted under an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), to develop and commercialize Cidara's Cloudbreak drug-Fc conjugates, DFCs, for the prevention of seasonal and pandemic influenza. The Phase 2a trial, which dosed its first healthy volunteer on September 10th, is a single-center, randomized, double-blind, placebo-controlled, proof-of-concept study to assess the prophylactic antiviral activity, safety, tolerability and pharmacokinetics of CD388 against influenza via a human viral challenge model, and to explore the impact of dose levels on efficacy. Multiple dose levels of CD388 will be evaluated in volunteers who will receive a single administration of CD388 or placebo prior to influenza viral challenge. The trial is expected to enroll up to 168 healthy adults. "The initiation of this Phase 2a trial is an important milestone, as it represents the first study in which CD388's prophylactic potential against influenza will be examined in humans," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "Because of its mode of action, CD388 has the potential to enable universal influenza coverage against all viral strains for all people, including those with compromised immune systems. We look forward to announcing the findings next year, and continuing our collaboration with Janssen who will be spearheading late-stage development."

08:07 EDT Acasti Pharma appoints Kohli as Chief Commercial Officer - The Company announces that Prashant Kohli has been named Chief Commercial Officer. Kohli previously served as Acasti's VP of Commercial Operations and held the same title at Grace Therapeutics, prior to its acquisition by Acasti in August 2021.

08:07 EDT Clovis submits sNDA with FDA and Type II variation with EMA for of Rubraca - Clovis Oncology announced that it has submitted a supplemental New Drug Application sNDA with the US Food and Drug Administration and a Type II variation with the European Medicines Agency for approval of Rubraca or rucaparib as first-line maintenance treatment for women with advanced ovarian cancer regardless of biomarker status who have responded to first-line platinum-based chemotherapy. The Company believes that the encouraging PFS results, the primary endpoint of the study, are strongly supportive of an approval and of use in the front-line setting and are grateful for the support of the clinical community familiar with the results. The submissions were based on the positive data from the monotherapy analysis of the randomized, Phase 3 ATHENA trial. These data demonstrated that Rubraca as first-line maintenance treatment significantly improved investigator-assessed progression-free survival compared with placebo in women with advanced ovarian cancer irrespective of biomarker status in each of the populations studied. "We believe the compelling PFS results, the primary endpoint of the ATHENA-MONO trial, are strongly supportive of an approval and reinforce the potential of Rubraca as an important new first-line maintenance treatment for ovarian cancer," said Patrick J. Mahaffy, President and CEO of Clovis Oncology. "We are grateful to the patients who participated in the trial and for the support of the clinical community familiar with these results."

08:06 EDT Waste Management acquiring controlling stake in Avangard Innovative's U.S. firm - Waste Management has agreed to acquire a controlling interest in Avangard Innovative's U.S. business, which will operate as Natura PCR - an independent company expected to scale and grow recycling capacity to produce an estimated 400 million pounds per year of post-consumer resin, or PCR, in five years. Through Natura PCR, WM expects to deliver new recycling capabilities for its customers and provide circular solutions for films and clear plastic wrap used commercially, such as plastic stretch wrap for pallets, furniture film, grocery bags and potentially shrink wrap around food and beverage containers. Natura PCR will focus on the mechanical recycling of film and flexible plastics and converts these materials to PCR that can be used to manufacture new products replacing virgin materials. WM expects to increase the volume of PCR pellets that Natura PCR can produce for use in new products. Natura PCR plans to grow recycling capabilities at Avangard's existing plant in Waller, Texas, and build new plant capacity in the Midwest. Avangard and affiliated entities will hold a collective minority equity position in Natura PCR. WM expects to receive investment returns comparable to its previously announced automation investments in single-stream recycling. The transaction is expected to close in late 2022.

08:06 EDT Pardes Biosciences commences Phase 2 trial of PBI-0451 - Pardes Biosciences reported commencement of a Phase 2 double-blind, randomized study to evaluate the antiviral activity, safety, and efficacy of orally administered PBI-0451 compared with placebo in non-hospitalized symptomatic adults with COVID-19 who are not at increased risk of progressing to severe illness. Pardes Biosciences expects to enroll 210 patients in the Phase 2 clinical trial at approximately 75 sites within the United States. Study eligibility will include symptoms of COVID-19 for 5 or less days and a positive test for SARS-CoV-2 infection. Use of concomitant medications for underlying health conditions will not be restricted in the clinical trial. Participants will be administered PBI-0451 orally with food, twice daily, at a 700 mg dose or placebo over five days. The primary objective will be to determine the proportion of patients below the limit of detection in nasal swab samples for infectious SARS-CoV-2 on day three. Secondary objectives will include assessments of safety and tolerability, time to sustained clinical recovery through day 28 defined as key COVID-19 symptoms, and hospitalizations and deaths. In a Phase 1 clinical trial, PBI-0451 at single and multiple doses demonstrated favorable tolerability without any study drug discontinuations and there were no treatment emergent drug-related adverse events assessed as greater than mild in severity. Additionally, no direct drug-related adverse findings were observed in 14-day or 28-day toxicology studies conducted across multiple preclinical species. PBI-0451 does not require ritonavir boosting and has the potential to be used broadly due to a favorable drug-drug interaction profile.

08:05 EDT Salarius Pharmaceuticals CEO issues letter to stockholders - Salarius Pharmaceuticals issued the following letter to stockholders from its President and Chief Executive Officer, David Arthur. "This past year, and particularly the past few months, have been busy, productive and rewarding for Salarius... Seclidemstat. Enrollment in our Phase 1/2 clinical study in Ewing and other FET-rearranged sarcomas is progressing well. We recently announced the addition of several prestigious institutions to the study, bringing the total to 17 clinical trial sites with 25 separate locations. We remain on track to report interim sarcoma data later this year, with additional data being available as patients continue to enroll and are treated with seclidemstat. At the recent American Society of Clinical Oncology annual meeting, results from the rEECur study found that patients treated with topotecan plus cyclophosphamide demonstrated progression-free survival of only 3.5 months, and patients treated with high-dose ifosfamide demonstrated only 5.7 months of progression-free survival. We believe these Ewing patients need improved treatment options and that delaying disease progression or improving progression-free survival is a significant patient benefit. With the help of our investigators, we have enrolled a number of patients with first- and second- relapsed Ewing sarcoma... The study of seclidemstat is also progressing at the MD Anderson Cancer Center in an investigator-initiated hematologic, or blood cancer, clinical trial... We are excited to be collaborating with Volition, a multi-national epigenetics company, in the field of biomarker identification... And finally, the abstract titled "Pre-clinical investigation of the LSD1 inhibitor, SP-2577 in a Small Cell Lung Cancer" was recently accepted for presentation at the American Association of Cancer Research Special Conference on Cancer Epigenomics to be held in Washington, D.C. on October 6-8, 2022. SP-3164. In January 2022 we acquired an intellectual property portfolio including the drug candidate SP-3164, which now forms the basis of our targeted protein degradation development program... Underscoring the commercial success of this class, global sales of first-generation molecular glues exceeded $16 billion in 2021. We are currently planning to develop SP-3164, a next-generation molecular glue, to treat lymphomas, multiple myeloma and potentially solid tumors, and we believe the potential for SP-3164 is significant. The value of SP-3164 lies in the fact it is the preferred half - or preferred enantiomer - of the widely studied drug avadomide, but is considered a new chemical entity with the potential for increased efficacy and improved safety when compared to avadomide....Since acquiring SP-3164 we have made great progress including completing the pre-Investigational New Drug meeting process with the U.S. Food and Drug Administration, which provided valuable input and clarity on preclinical, clinical and other regulatory matters for preparing and submitting an IND application.... we believe we remain on track for an IND submission in the first half of next year and the start of clinical studies soon thereafter. We are looking forward to providing an update on this ongoing preclinical research later this year at the 5th Annual Targeted Protein Degradation Summit to be held in Boston, Massachusetts on October 25-28, 2022.... As of June 30, 2022, Salarius had cash, cash equivalents and restricted cash of $22.6 million, and while we expect SP-3164 R&D expenses to ramp up in 2022 and 2023, we believe planned operations are funded well into 2023."

08:03 EDT HeartSciences reports $4.3M in cash as of July 31 - As a development-stage company, there were no meaningful revenues for the first quarter of 2023. As of July 31, 2022, cash and cash equivalents were $4.3 million. The Company continues to carefully manage its expenses and believes it has sufficient capital to support operations beyond resubmission for FDA De Novo clearance.

08:03 EDT HeartSciences on track to resubmit FDA De Novo clearance in current fiscal year - Andrew Simpson, Chief Executive Officer of HeartSciences, commented, "We are nearing completion of patient recruitment for the FDA pivotal clinical validation study of the MyoVista wavECG device with over 500 patients recruited out of an overall target of 550 patients. We expect to report study results following its completion. Assuming a successful outcome, we remain on track to resubmit for FDA De Novo clearance in the current fiscal year. We are seeking to address one of the most significant needs in healthcare by making an ECG a far more valuable cardiac screening tool. The growing body of published ECG research demonstrates that ECGs can have far greater clinical value. Our first device, the MyoVista, leverages AI machine learning to detect cardiac dysfunction that cannot be diagnosed by current conventional ECGs and its technology has been the subject of several published studies in elite cardiology journals. As a result, we believe we are positioned at the forefront of what is expected to be a new era for ECGs. The Company has benefited from approximately $60 million of investment to date and has built an extensive intellectual property portfolio. We intend to continue to add patents to further strengthen our long-term IP protection as we move towards commercialization. Ultimately, our goal is to make MyoVista the new standard of care, particularly in the frontline or point-of-care clinical setting. In fact, according to Allied Market Research, the global ECG market was valued at $8.3 billion in 2020 and is projected to reach $18.4 billion by 2030. Furthermore, during the first quarter of fiscal 2023, we completed our initial public offering with gross proceeds of approximately $6.375 million. The IPO significantly enhanced our balance sheet provides us with sufficient expected cash runway to execute on key upcoming milestones, including completing our FDA pivotal study and resubmission for FDA De Novo clearance."

08:01 EDT Vaxxinity announces first subjects dosed in Phase 1 trial of UB-313 - Vaxxinity announced that the first subjects have been dosed in a Phase 1 clinical trial of UB-313, a vaccine targeting calcitonin gene-related peptide, for the preventive treatment of migraine. "Initiating this first-in-human study of UB-313 represents another milestone for Vaxxinity as we continue to expand our clinical pipeline into chronic conditions using our unique peptide vaccine platform," said Mei Mei Hu, Chief Executive Officer of Vaxxinity. "An anti-CGRP vaccine has the potential to disrupt the migraine paradigm by offering longer-lasting relief, more convenient administration, and affordable access. Our vision is to help migraine patients worldwide reclaim their lives with UB-313."

07:49 EDT Avant Brands announces additions to Treehugger product portfolio - Avant Brands announced the launch of Organic Sweet Fuel OG Flower & Pre-Rolls to the Treehugger product portfolio, available September 6, 2022, at the Ontario Cannabis Store. This is Treehugger's first whole flower product, in addition to its existing Organic King Tut pre-roll product.

07:46 EDT Radcom renews initial contract signed in 2019 with Rakuten Mobile - Radcom announced that it has renewed its initial contract signed in 2019 with Rakuten Mobile. With this renewal, Radcom will continue its successful partnership with Rakuten Mobile, providing advanced cloud-native assurance solutions for Rakuten Mobile's network in Japan.

07:40 EDT Innovation Pharmaceuticals provides update on BT BeaMedical investment - Innovation Pharmaceuticals updated shareholders on recent progress by BT BeaMedical Technologies to advance its new image guided surgical laser platform for treating previously inoperable cases of epilepsy and for enabling new treatment options for cancer cases in multiple specialties. In June 2022, the Company announced acquiring an interest in BeaMed. BeaMed has informed the Company that it has initiated important software integration work; engaged regulatory agencies on appropriate development steps via the 510(k) pathway; formalized a distribution relationship with Fortec Medical which has access to over 2700 hospitals in the U.S.; and identified key opinion leaders to serve in scientific advisory capacities. BeaMed anticipates additional value-added events to occur as it aims to reshape laser guided surgery with its unique directed laser technology system.

07:37 EDT Monarch Mining announces drill results from 2022 program at McKenzie Break - Monarch Mining reports initial drill results from the 2022 drilling program on its wholly-owned McKenzie Break gold project, located 25 kilometres north of the Corporation's wholly owned 750 tonne-per-day Beacon mill. The 2022 drilling program on the McKenzie Break property began in April and is progressing well, with three surface drill rigs in operation and 29 holes drilled to date, for a total of 6,798 metres. The program is aimed at expanding the size of the currently proposed pit in the up-dip direction, increasing the current underground resource to the east and north and testing additional exploration targets along the volcanic-intrusive contact to the south. Monarch will continue testing the deposit with holes at 50-metre centres. "The McKenzie Break mineralization is still open in all directions, and the near-surface intersections we are seeing confirm that the proposed pit limits can be extended westward," said Jean-Marc Lacoste, President and Chief Executive Officer of Monarch. "The remainder of the drilling program will continue to test the limits of the mineralization in all directions, as well as several exciting regional exploration targets."

07:36 EDT Shyft secures initial pre-order for Blu Arc All-Electric delivery walk-in vans - Blue Arc EV Solutions, a new brand of The Shyft Group, made its debut in March with the industry-first commercial grade purpose-built EV chassis; a fully reimagined from the ground up all-electric Class 3 delivery walk-in van; and a fully portable, remote-controlled charging station, the Power Cube. Today, Shyft announced the first pre-order for its all-electric Class 3, 4 and 5 walk-in delivery vans from Randy Marion Automotive Group, one of the largest dealer groups in the Carolinas. "I am extremely proud of the work the Shyft team has done positioning Blue Arc EV Solutions to meet customer needs," said Shyft CEO Daryl Adams. "From the beginning just 14 short months ago, we've been confident in our EV commercial vehicle design because we have served last-mile delivery customers for nearly 50 years. We've hit all of our critical development milestones and most recently we've validated that our range will meet our customers' expectations and this shows not only do we know what they need, we are delivering it." With Shyft's existing coast-to-coast manufacturing and service infrastructure, it is primed to deliver EV solutions at scale. Following receipt of government approvals by this winter, Shyft expects to finalize a multi-year purchase order with Randy Marion for the pre-ordered walk-in vans, begin production in the Midwest and start delivery to Randy Marion in mid-2023. Fleet customers will be able to pre-order online or at the dealerships starting in September.

07:35 EDT Aehr Test Systems receive wafer level burn-in system order from new customer - Aehr Test Systems announced it has received a purchase order from a new customer for a FOX-NPTM multi-wafer test and burn-in system, multiple WaferPak Contactors and a FOX WaferPak Aligner to be used for qualification of Aehr's wafer level burn-in solution for silicon carbide devices for electric vehicles and other markets. This company is a major supplier of silicon carbide devices serving several significant markets including the electric vehicle industry. This order has acceptance criteria including demonstrating certain new enhancements and functionality criteria offered by Aehr and stipulated under a corresponding evaluation and acceptance agreement. Upon successful completion of the specified criteria, final acceptance of the purchase order is met, and title transfer and invoicing will be completed. This FOX system is configured for stress testing and burning in 150mm and 200mm silicon carbide wafers using Aehr's proprietary WaferPak full wafer Contactors. The FOX-NP system and FOX WaferPak Aligner are scheduled to ship this week to the customer's facility. Gayn Erickson, President and CEO of Aehr Test Systems, commented, "We are very excited that this new customer has chosen to move forward with us after we demonstrated the capability and configurability of the FOX platform full wafer test and burn-in solution using our systems and their silicon carbide wafers at our facility in Fremont, California. This company has indicated to us that no other provider has a product that is scalable to high volume production like Aehr's FOX-XP multi-wafer system. The FOX-NP system is a two-wafer system that is fully compatible with the volume production FOX-XP, which can be configured with up to nine or eighteen wafers depending on the customer's specific test requirements and power configuration. This allows our customers to choose between larger and smaller configuration systems that are 100% compatible with each other at their facilities around the world. The purchase order for the FOX-NP system includes specific performance and functionality evaluation criteria that we believe Aehr will achieve on their test floor during the next three to six months which triggers final acceptance of the solution. They have provided us with forecasts for our FOX-XP systems for volume production of their silicon carbide devices at multiple facilities around the world, with initial delivery for our FOX-XP systems requested during this fiscal year ending May 31, 2023."

07:34 EDT Akanda enters exclusive European license agreement with Cookies - Akanda announced an exclusive license agreement with iconic international cannabis lifestyle brand Cookies. The multi-year agreement enables Akanda to pursue the current medical and future adult-use opportunities in Europe. Under the terms of the license agreement, Akanda gains the ability to cultivate, manufacture and distribute Cookies strains, and the rights to sell Cookies branded products, including non-cannabis merchandise, in Portugal. Akanda intends to initially produce EU GMP certified Cookies branded high THC medical cannabis products at its indoor premium cultivation and manufacturing facility in Sintra, Portugal. Additionally, Akanda is able to exclusively open and operate flagship Cookies branded pharmacy outlets throughout the country.

07:33 EDT PyroGenesis selected by advanced materials, chemicals trading house - PyroGenesis Canada announces that it has been chosen by an advanced materials and chemicals trading house in the Southern hemisphere to provide the Company's SPARC refrigerant waste destruction system. The Client's name will remain confidential for competitive reasons. The system is the first of two systems that the company has indicated they may require. With engineering services, ancillary equipment options, and after-sales support, the ultimate project cost will be between USD$2-5MM per system depending on final decisions regarding full deliverables and the final agreement is expected to be signed before the end of Q2 2023. "The SPARC technology is one of the Company's first major technology achievements, which I believe speaks to our foresight, and our continued R&D, that a legacy system such as this can be used to address recent trends we are all seeing, evidenced by the increased demand for environmentally-friendly waste destruction systems - especially those geared to the destruction of dangerous or polluting chemicals and gases," said P. Peter Pascali, CEO and Chair of PyroGenesis. "Jurisdictions worldwide are tightening regulations surrounding hazardous waste disposal, while at the same time trying to stimulate the safe destruction of hydrocarbons such as refrigerant chlorofluorocarbons, by providing carbon credits to offset costs. This announcement today underscores the fact that companies are increasingly recognizing the major role that PyroGenesis' fossil-free waste destruction systems can play in this movement. Land-based systems such as our SPARC(TM) build upon the foundation of success we have established previously with our ship-board waste destruction systems for the U.S. Navy's Gerald R. Ford-class aircraft carriers."

07:32 EDT Great Panther Mining signs LOI with Newrange to sell Coricancha Mine in Peru - Great Panther Mining announces that it has signed a non-binding Letter of Intent with Newrange Gold to sell 100% of the company's Peruvian subsidiaries, Great Panther Silver Peru S.A.C. and Great Panther Coricancha S.A.C., which hold the Coricancha Mine in Peru, for a total purchase price of $750,000 payable in cash. Coricancha, located in the central Andes of Peru approximately 90 kilometres east of Lima, is a past producing mine with an extensive land package in the prolific Central Polymetallic Belt in Peru. The project is currently in care and maintenance and includes an operational 600 tonne per day mill, an underground mine and supporting infrastructure. Completion of the Transaction is subject to certain conditions including, but not limited to, the completion of definitive documentation, completion of financing by Newrange and receipt by the company and Newrange of all necessary third-party consents and approvals, including the approval of the company's proposal trustee, the court in the company's proposal proceedings and, in the case of Newrange, the approval of the TSX Venture Exchange.

07:18 EDT Ascot Resources reports assay results from Big Missouri deposit - Ascot Resources announced the first batch of assay results at the Big Missouri deposit from the 2022 exploration drill program at the Company's Premier Gold Project located on Nisga'a Nation Treaty Lands in the prolific Golden Triangle of northwestern British Columbia. These results are from surface drilling for in-fill and exploration purposes at the Big Missouri deposit, approximately six kilometres north of the past-producing Premier mill. Highlights from the drill results include: 71.28 g/t Au and 23.00 g/t Ag over 2.00m from a depth of 57.74m in hole P22-2405, including 136.50 g/t Au and 39.7 g/t Ag over 1.00m; 5.09 g/t Au and 6.60 g/t Ag over 12.00m from a depth of 37.50m in hole P22-2404, including 7.17 g/t Au and 6.70 g/t Ag over 7.50m; 3.28 g/t Au and 7.40 g/t Ag over 14.65m from a depth of 78.31m in hole P22-2412, including 15.74 g/t Au and 6.8 g/t Ag over 2.51m; 16.55 g/t Au and 25.40 g/t Ag over 2.00m from a depth of 57.00m in hole P22-2406, including 29.90 g/t Au and 47.0 g/t Ag over 1.00m. To date, 46 holes have been completed for a total of 4,260 metres at the Big Missouri deposit this season. This release summarizes the assay results from the first 15 drill holes for a total of 1,195 metres from surface pad BM-1/22. Drill holes were targeting the A Zone of the Big Missouri deposit in planned stoping areas, potential extensions of stopes, and gaps in previous drilling on the deposit. Derek White, President and CEO of Ascot commented, "This season's drill program at Big Missouri is important as it enables us to refine and gain more confidence on our initial stoping areas for underground mining. We are pleased to see high-grade intercepts and visible gold encountered in the first batch of assay results from this area. The drilling revealed various locations where planned stope shapes can be extended, where existing stope shape geometry was confirmed, and provide useful information in previously undrilled gaps in the historical database. We look forward to seeing continued success from the drill program at Big Missouri this season, and in combination with ongoing underground development and sampling, vastly improving the confidence in our geological model at PGP as we advance towards production."

07:16 EDT Medicenna announces clinical collaboration with Merck on MDNA11 with KEYTRUDA - Medicenna Therapeutics (MDNA) announced that it has entered into a clinical trial collaboration and supply agreement with Merck (MRK) to evaluate MDNA11, Medicenna's "beta-only" long-acting IL-2 super-agonist in combination with KEYTRUDA, Merck's anti-PD-1 therapy, in the ongoing Phase 1/2 ABILITY Study. The ABILITY Study is a Phase 1/2 trial designed to assess the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of MDNA11 as a monotherapy and in combination with KEYTRUDA in patients with advanced/metastatic solid tumors. Under the terms of the clinical trial supply and collaboration agreement, Medicenna will sponsor the study and Merck will supply KEYTRUDA. The two companies will establish a Joint Development Committee to optimally advance the study's combination arm. "Entering into this agreement with Merck provides us with an opportunity to work with the world's leading immuno-oncology company," said Fahar Merchant, PhD, President and CEO of Medicenna. "Although we believe that MDNA11 has great potential as a single agent, combining it with KEYTRUDA may significantly enhance therapeutic benefit in different types of cancer, potentially maximizing the value of MDNA11. We are fortunate to have the opportunity to explore MDNA11 in combination with KEYTRUDA. MDNA11 is designed to selectively expand CD8 T and NK cells, as well as increase PD-1 expression on immune cells. With strong preclinical data demonstrating promising activity with anti-PD-1, we look forward to the opportunity to evaluate the efficacy of MDNA11 in combination with KEYTRUDA in various solid tumors," added Dr. Merchant.

07:14 EDT BeyondSpring presents new data on plinabulin - BeyondSpring announced data from a poster presentation at the ESMO Congress 2022 being held September 9-13, 2022, in Paris, France. The poster includes a new analysis from the Phase 2/3 PROTECTIVE-1 and PROTECTIVE-2 trials. The data provides evidence of protection of bone marrow granulocyte-monocyte progenitor stem cells within 24 hours after chemotherapy based on an evaluation of peripheral immature and mature neutrophil counts. Poster Presentation Details: Title: "Clinical Evaluation of Plinabulin's Granulocyte-Monocyte Progenitor Stem Cell Effects for the Prevention of Chemotherapy-Induced Neutropenia." Peripheral blood counts for mature and immature neutrophils, white blood cells, red blood cells and platelets were obtained from LabCorp. The blood counts were analyzed before and 24 hours after chemo administration without or with plinabulin. The absolute neutrophil count with and without plinabulin was comparable at pre-dose C1D1 but was significantly higher at 24 hours post-chemo dose with plinabulin vs. control. At 24 hours post-chemo dose, the mean ANC had increased by 3.2 x 109/L with plinabulin whereas the mean ANC had decreased by 0.55 x 109/L with the control due to the myelosuppressive effect of TAC chemotherapy. Pre-dose, the proportion of patients with a GMP-derived immature cell count value greater than0 was ~0 for both the plinabulin and control arms. At 24 hours post-chemo, the number of patients with an immature neutrophil count greater than0 had significantly increased with plinabulin but not with the control. The proportion of patients with immature cells from all other WBCs and RBCs was ~0 at pre- or post-chemo dose with or without plinabulin.

07:13 EDT Cellebrite announces collaboration with Lake Jackson Police Department - Cellebrite DI announced their collaborative work with the Lake Jackson Police Department. The department is utilizing Cellebrite UFED 4PC, Cellebrite Physical Analyzer, and Cellebrite UFED Cloud.

07:11 EDT Amryt Pharma announces new patent for Mycapssa - Amryt announces an update regarding the patents for its product Mycapssa. The USPTO has issued to Amryt US Patent No. 11,400,159, with claims related to the Mycapssa product. This patent will expire in September 2029. Amryt has nine Orange Book-listed patents for Mycapssa with patent protection through December 2040. Dr Joe Wiley, CEO of Amryt Pharma, commented: "We are always working to develop and extend our IP portfolio and today's news further illustrates the robust IP protection enjoyed by Mycapssa"

07:09 EDT ObsEva board authorizes termination of 70% of employees - ObsEva announced an update on its previously announced restructuring efforts. Reduction-in-force: The Board of Directors has authorized the termination of approximately 70% of employees, including Katja Buhrer, Chief Strategy Officer. The Company expects to substantially complete the terminations during the fourth quarter of 2022, and to achieve savings of approximately $7.6M on an annual basis, which represents estimated cash compensation related to salary, bonus, and benefits to affected employees. The remaining employees will support the Company's existing license agreements, namely its global license agreement with Organon International for the development and commercialization of ebopiprant and its sublicense agreement with Hangzhou Yuyuan BioScience Technology Co for the development and commercialization of nolasiban in the People's Republic of China. Assignment of linzagolix agreements: The Company has assigned multiple contracts related to the ongoing development of linzagolix to Kissei Pharmaceutical. To date, contracts with commitments of approximately $6.2 million have been assigned to Kissei, including $1.7M in accounts payable. The Company continues to work to assign other contracts related to linzagolix to Kissei and expects to complete the transition of the linzagolix program by October of this year. Moratorium update: As previously announced, ObsEva has applied to the competent court in Geneva, Switzerland, for a court-sanctioned moratorium. The courts have stipulated a deadline of September 23, 2022 for the Company to submit an audited balance sheet as of June 30, 2022. Upon receipt of the audited balance sheet, the Company expects the court to schedule a date for its first hearing. If granted, the moratorium will provide the Company with temporary protection against debt-enforcement and bankruptcy proceedings in Switzerland, with a view to make it possible for the Company to undertake additional restructuring measures under the supervision of one or more court-appointed administrators. Nasdaq non-compliance notice update: As previously announced, the Company received a notification letter from The Nasdaq Stock Market advising the Company that it was not in compliance with Nasdaq Listing Rule 5450(b)(1)(A) requiring companies listed on the Nasdaq Global Select Market to maintain a minimum of $10,000,000 in stockholders' equity for continued listing. The Company submitted its plan to regain compliance on August 29, 2022. Additionally, on September 12, 2022 the Company received a notification letter from Nasdaq advising the Company that it was not in compliance with Listing Rule 5450(a)(1) because, for a period of thirty consecutive business days, the bid price of ObsEva's common shares had closed below the minimum $1.00 per share requirement for continued listing. The notification has no immediate effect on the listing or trading of the common shares on the Nasdaq Global Select Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until March 13, 2023, to regain compliance with the minimum bid price requirement. The Company will regain compliance with the minimum bid price requirement if at any time during the 180-day period, the bid price of the Company's common shares closes at or above $1.00 per share for a minimum of ten consecutive business days. The Company intends to monitor the closing bid price of the Company's common shares and may, if appropriate, consider implementing available options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules. In addition to compliance with the continued listing requirements noted above, Nasdaq may use its discretionary authority to delist the Company's common shares in connection with the court-sanctioned moratorium in Switzerland.

07:07 EDT Guardforce announces LOI to acquire Shenzhen Kewei Robot Technology - Guardforce AI announced it has signed a non-binding letter of intent, LOI, with Shenzhen Intelligent Guardforce Robot to acquire Shenzhen Kewei Robot Technology Company Limited, a high-tech robotics company specializing in developing robotics software solutions and robotics management platforms, as well as robotics sales and technical services. This agreement supersedes and replaces the previously announced LOI with Kewei to acquire 12 of its subsidiary companies, and the terminated securities purchase agreement pursuant to which the Company had intended to acquire 7 of its subsidiary companies. The purchase price and consummation of the acquisition of Kewei are subject to the satisfactory completion of the Company's due diligence and an independent audit, as well as a third-party valuation and fairness opinion. The Company plans to pay for this acquisition through a combination of cash and restricted common stock of the Company at a value of no less than $1 per share. Guardforce AI expects to enter into a definitive purchase agreement with Kewei relating to this acquisition within the next few months. Olivia Wang, Chairwoman and Chief Executive Officer of Guardforce AI, added, "After conducting further due diligence, it became clear that acquiring Kewei itself, compared to acquiring only the Kewei sales channel subsidiaries, would add both a premier roster of business clients, as well as advanced technologies that we believe will help to accelerate our strategic expansion within the robotics industry worldwide. Overall, we remain focused on our goal to transform Guardforce AI into a leading integrated security company in AI and robotics."

07:06 EDT LHC Group forms joint venture with University of Maryland Medical System - LHC Group and University of Maryland Medical System - UMMS - signed a definitive agreement to form a new joint venture partnership to provide enhanced in-home healthcare services throughout a large portion of the state of Maryland. The partnership's combined assets will include multiple locations serving 20 Maryland counties, the city of Baltimore, and the greater metropolitan area. It is anticipated that the agreement will be finalized in Q4, subject to customary closing conditions, at which time LHC Group will purchase majority ownership and assume management responsibility. LHC Group expects incremental annualized revenue from this joint venture of approximately $4.8M and that it will not materially affect its 2022 diluted EPS. UMMS is a private, university-based regional health system focused on Maryland.

07:05 EDT IsoPlexis announces publication of initial data off its CodePlex platform - IsoPlexis Corporation announced the publication of initial data off its CodePlex platform in the journal Scientific Reports carried out by researchers at the Shanghai Institute of Hematology. In the paper titled "Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells," IsoPlexis' first APAC region publication, researchers investigated whether CD19 CAR-T cells that secrete IL-17 show a persistent and enhanced anti-tumor response. The researchers observed that in mice treated with CAR-T cells, cytokine expression measured with IsoPlexis' CodePlex platform suggested that IL-7 secretion promoted a Th1 functional phenotype to drive anti-tumor activity more effectively. This initial data generated using IsoPlexis' CodePlex solution indicates that the platform can provide key insights into cytokine signatures of CAR-T products to characterize function for improved persistence and potency. "This initial APAC publication further strengthens IsoPlexis' expansion in the region and demonstrates key initial interest in the ability for CodePlex's effortless automation to fit an important proteomic need internationally," says Sean MacKay, CEO of IsoPlexis.

07:04 EDT Rubius Therapeutics discontinuing Phase 1 clinical trials of RTX-240, RTX-224

07:04 EDT ProMIS Neurosciences appoints Farfel as Chief Executive Officer - ProMIS Neurosciences announced that it has appointed Gail Farfel, Ph.D., as Chief Executive Officer, CEO, effective September 19, 2022. Gail Farfel, Ph.D., has over 25 years of experience in large and small pharma, including venture-backed and public companies. Prior to joining ProMIS, Farfel served as Executive Vice-President and Chief Development Officer of Zogenix. "After an extensive search, we are confident that under Gail's leadership ProMIS can achieve its tremendous potential. ProMIS' Board and management welcome her to the CEO role as we work to complete the transition to a clinical stage, multi-product, Nasdaq listed company," stated Eugene Williams, ProMIS Chairman and Co-Founder.

07:03 EDT Hamilton Lane names Kristin Brandt as Chief Human Resources Officer - Hamilton Lane (HLNE) announced that it has hired Kristin Brandt to the newly-created role of Chief Human Resources Officer, based in the firm's Conshohocken, Penn. headquarters and reporting into CEO Mario Giannini. Brandt is a longtime Human Resources professional with 25 years of experience, nearly 20 of which were within the financial services and banking industry. She comes to Hamilton Lane from Lazard (LAZ), where she spent seven years and most recently served as the Head of HR for the Americas Investment Banking division.

07:02 EDT Evogene's Canonic signs licensing agreement with GroVida - Canonic Ltd., a wholly owned subsidiary of Evogene, announced that it has signed a non-exclusive licensing agreement with leading Portugal-based cannabis cultivation and manufacturing company, GroVida Lda. Under the agreement, GroVida will cultivate, market and sell products based on Canonic's cannabis varieties in Europe and the United Kingdom, and will pay Canonic royalties on its sales based on these products. This is Canonic's initial licensing agreement for the European market, a key target market for Canonic, with total medical cannabis market sales estimated at approximately EUR400M for 2021, while still at an early stage in its development.

06:57 EDT Viavi announces $300M share repurchase program - Viavi announced that its board of directors has authorized a stock repurchase program of up to $300M of Viavi's common stock effective October 1 and will remain in effect until the amount authorized has been fully repurchased or until Viavi suspends or terminates the program. This new program replaces the $200M stock repurchase program that the board previously authorized in September 2019 and which expires September 30. Under the new share repurchase program, the company is authorized to repurchase shares through a variety of methods, including open market purchases, privately-negotiated transactions or otherwise in accordance with applicable federal securities laws, including through Rule 10b5-1 trading plans. The timing of repurchases under the new program will depend upon business and financial market conditions.

06:46 EDT Lazard reports preliminary AUM $217B as of August 31 - Lazard reported that its preliminary assets under management as of August 31 totaled approximately $217B. The month's AUM included market depreciation of $5.2B, foreign exchange depreciation of $2.2B, and net outflows of $0.7B.

06:33 EDT Ingersoll-Rand to acquire Pedro Gil, closes Westwood Technical acquisition - Ingersoll Rand has entered into an agreement to acquire Pedro Gil and acquired Westwood Technical for a combined upfront cash purchase price of approximately $30M. Pedro Gil is a manufacturer of positive displacement blowers, pumps and vacuum systems in the Spanish market. Pedro Gil has annual revenue of approximately $15less than and will join the Industrial Technologies and Services segment. Westwood Technical is a control and instrumentation specialist based in the U.K. with IIoT capabilities. Westwood Technical expands Ingersoll Rand's IIoT offerings with its Aircom product line, a self-contained, battery-powered communications device utilizing LoRaWAN technology to transmit data from assets in remote and challenging locations for monitoring and control applications. Westwood Technical will join Ingersoll Rand's Precision and Science Technologies segment. The acquisition of Westwood Technical closed on September 1. The acquisition of Pedro Gil is expected to be completed during Q4.

06:08 EDT Barnwell Industries sells drilling rig, provides Canadian oil and gas update - Barnwell Industries reported the sale of drilling rig by its wholly-owned Water Resources International subsidiary for net consideration of approximately $550K. The sale will result in a gain to be recognized in Q4. The company is taking these actions to reduce contract drilling operating costs and still owns 5 rigs for drilling and pump installation. In the North Twining Unit in which Barnwell holds a 29% interest, there are now five horizontal wells on production with a sixth to come online at the end of September. Barnwell's share of the current pre-royalty, combined production is 350 barrels of oil, 60 barrels of natural gas liquids and 2,000 MCF of natural gas per day. The NTU drilling program has greatly exceeded expectations. Current pre-royalty production is at 55 barrels of oil, 6 barrels of natural gas liquids and 200 MCF of natural gas per day. Installation of a wellhead compressor has been delayed due to supplier issues, but is still expected to increase production further once it is installed in October.

06:05 EDT National Energy Services awarded contract in Saudi Arabia - National Energy Services has announced that the company has been awarded a long term contract for Directional Drilling services in the Kingdom of Saudi Arabia, covering Directional Drilling, or DD, Measurement while Drilling, or MWD, Performance Drilling, Well Engineering and Logging While Drilling, or LWD, services for up to four years starting with immediate effect. This award reflects the culmination of several years of research and development investment in several field trials to demonstrate NESR's ability to drill and deliver vertical and directional wellbores in record times with leading-edge technologies. Over the last year, NESR's successful partnership with Phoenix Technology Services has led to several DD records across several fields which have saved significant drilling time for customers. This award also provides NESR the platform for the introduction of next generation technologies in the drilling and measurement spheres which the Company anticipates introducing over the course of this contract.

06:02 EDT Lumen CEO Jeff Storey to retire, Kate Johnson to succeed - Lumen announced Kate Johnson has been appointed president, CEO and a member of the company's board of directors with the transition date expected to be November 7. Johnson succeeds Jeff Storey, who has announced his retirement after a distinguished 40-year career within the telecommunication and technology industries, including Lumen and its predecessors. Storey will remain with the company through December 31 to ensure a transition.

05:48 EDT UBS plans to raise dividend, extend share buyback - UBS said in a statement that it will adjust its accrual for the 2022 ordinary dividend from 51c to 55c per share - an increase of 10% compared to the previous year. The Board intends to propose the dividend for approval by shareholders at the Annual General Meeting to be held in 2023. In addition, UBS expects share repurchases to exceed the $5B goal for the year 2022. As of September9, 2022, UBS has bought back $4.1B of shares. UBS said: "We will provide guidance on next year's capital return at our fourth quarter earnings presentation and expect to continue to have share repurchases and a progressive dividend."

05:19 EDT AT&T CEO John Stankey provides shareholder update at Goldman Sachs conference - John Stankey, CEO, AT&T, spoke at the Goldman Sachs Communicopia + Technology Conference where he provided an update to shareholders. Stankey said that AT&T continues to take a disciplined and return-focused approach to growth and investment and made the following points: "The company continues to add customers in its strategic focus areas of 5G and fiber. Stankey shared he feels comfortable with AT&T's business trajectory and the continued customer demand it is seeing. Overall industry postpaid phone volumes remain healthy, and AT&T's consistent go-to-market approach, along with an improved customer experience, is attracting high-value customers. Stankey said AT&T is developing diversified sources of growth, with wireless share gain in specific customer cohorts, such as the public sector and large and mid-sized business. He expects this momentum to continue thanks to a strong distribution ecosystem, a high-performing workforce and enhanced network quality strengthened by recent mid-band 5G spectrum deployments. He also added that recent pricing actions are performing as anticipated, supporting the company's view that these actions will be accretive in the latter half of the year. Stankey shared that AT&T Fiber continues to deliver the best customer experience in the marketplace and that he's pleased with the penetration rates for new fiber build. As AT&T expands to new markets, the company has seen first-year penetration rates about two times greater than historical norms. Stankey expects subscriber momentum and current penetration rates to continue based on the company's improved ability to build fiber effectively and the strong customer demand for the product. Fiber ARPU continues to grow, and the company is seeing higher than anticipated uptake of its multi-gig fiber offerings. AT&T continues to expand its fiber footprint and has the ability to serve 18 million customer locations in more than 100 metro areas with AT&T Fiber. Stankey shared there may be an opportunity to expand the company's fiber footprint based on the attractiveness of returns and that government subsidies supporting public-private partnership are expected to help drive broadband expansion. AT&T remains focused on its cost transformation program and its efforts to achieve more than $4 billion of its $6 billion run-rate cost savings target by the end of the year. Stankey noted that he's comfortable with AT&T's cost structure, and believes the company can continue to drive out costs as it exits portions of its legacy businesses. This includes efforts to transition from its legacy copper network to fiber. Stankey shared that AT&T is investing at a record clip to fuel growth in core connectivity, while continuing to pay an attractive dividend, and that the company is focused on building a sustainable and durable connectivity operation with improved cash generation. AT&T is pleased with the return profile of its fiber and 5G investments and continues to expect 2022 and 2023 to be the peak of this capital investment cycle with capital intensity moderating in 2024 and beyond. Overall, the company's long-term capital allocation priorities remain unchanged, and it expects to use cash after dividends to reduce debt with a goal of reaching a net debt-to-adjusted EBITDA range of 2.5x."

05:13 EDT Nokia appoints Amy Hanlon-Rodemich as chief people officer - Nokia announced the appointment of Amy Hanlon-Rodemich as chief people officer and member of the group leadership team, effective October 24. Amy Hanlon-Rodemich joins Nokia from GlobalLogic, where she is chief people officer.

05:10 EDT Sight Sciences completes enrollment in SAHARA Trial - Sight Sciences announced the completion of enrollment in the SAHARA Trial, a first of its kind outcomes study designed to evaluate whether an interventional dry eye procedure with the TearCare System is superior in alleviating the signs and symptoms of dry eye disease compared to six-months of twice daily Restasis dry eye eyedrops. Primary endpoints measured by a masked assessor at six months include changes from baseline of Tear Breakup Time and Ocular Surface Disease Index Score. Results from the 310-patient, 1:1 randomized SAHARA trial are expected to be available in late Q2 2023.